

Vaccine

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

- 5 This invention concerns vaccines against *Neisseria meningitidis* and pneumococcus. In particular, it concerns vaccines based on conjugated capsular saccharides from multiple meningococcal and/or pneumococcal serogroups.

BACKGROUND ART

- 10 Based on the organism's capsular polysaccharide, twelve serogroups of *N. meningitidis* have been identified (A, B, C, H, I, K, L, 29E, W135, X, Y and Z). Group A is the pathogen most often implicated in epidemic disease in sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in USA and in most developed countries. Serogroups W135 and Y are responsible for the remaining cases in USA and developed countries.

- 15 A tetravalent vaccine of capsular polysaccharides from serogroups A, C, Y and W135 has been known for many years [1,2]. Although effective in adolescents and adults' it induces a poor immune response and short duration of protection and cannot be used in infants [e.g. ref. 3] because polysaccharides are T cell-independent antigens that induce a weak immune response which cannot be boosted. The polysaccharides in this vaccine are not conjugated [4].

- 20 Conjugate vaccines against serogroup C have been approved for human use, and include Menjugate™ [5], Meningitec™ and NeisVac-C™. Mixtures of conjugates from serogroups A+C are known [6-8] and mixtures of conjugates from serogroups A+C+W135+Y have been reported [9-13].

- 25 While meningococcal conjugates are well known, they have not yet been fitted into existing pediatric immunisation schedules, which for developed countries typically involve: hepatitis B vaccine at birth; and, starting at 2 months, all of diphtheria/tetanus/pertussis (D-T-P), H. *influenzae* type b (Hib) conjugate, inactivated poliovirus and pneumococcus conjugates at 2 months.

- 30 When adding conjugated vaccines to existing immunisation schedules, however, the issue of carrier-induced epitopic suppression (or "carrier suppression", as it is generally known) must be addressed, particularly suppression arising from carrier priming. "Carrier suppression" is the phenomenon whereby pre-immunisation of an animal with a carrier protein prevents it from later eliciting an immune response against a new antigenic epitope that is presented on that carrier [14].

- 35 As reported in reference 15, where several vaccine antigens contain the same protein component (being used as an immunogen and/or as a carrier protein in a conjugate) then there is the potential for interference between those antigens. In reference 15, the immune response against an antigen that was conjugated to a tetanus toxoid (Tt) carrier was suppressed by pre-existing immunity against Tt.

- 40 Reference 16 reports how a combination of D-T-P vaccines with a Hib conjugate vaccine was adversely affected where the carrier for the Hib conjugate was the same as the tetanus antigen from the D-T-P vaccine. The authors concludes that this

"carrier suppression" phenomenon, arising from interference by a common protein carrier, should be taken into account when introducing vaccines that include multiple conjugates.

- 5 In contrast to references 15 and 16, reference 17 reported that priming with tetanus toxoid had no negative impact on the immune response against a subsequently-administered Hib-Tt conjugate, but suppression was seen in patients with maternally acquired anti-Tt antibodies. In reference 18, however, an 'epitopic suppression" effect was reported for a Tt-based peptide conjugate in patients having existing anti-Tt antibodies resulting from tetanus vaccination.
- 10 In reference 19, it was suggested that a conjugate having CRM197 (a detoxified mutant of diphtheria toxin) as the carrier may be ineffective in children that had not previously received diphtheria toxin as part of a vaccine (e.g as part of a D-T-P or D-T vaccine). This work was further developed in reference 20, where a carrier priming effect by D-T immunization was seen to persist for subsequent immunization with Hib
- 15 conjugates. In reference 21, the authors found that pre-immunisation with a diphtheria or tetanus toxoid carrier protein reduced the increase in anti-Hib antibody levels after a subsequent immunization with the Hib capsular saccharide conjugated to those carriers, with IgG1 and IgG2 being equally affected.

- Responses to the carrier portions of the conjugates were also suppressed.
- 20 Furthermore, a more general non-epitope-specific suppression was seen, as pre-immunisation with one conjugate was seen to affect immune responses against both the carrier and saccharide portions of a second conjugate that was administered four weeks later.

- The use of different carrier proteins in a single multivalent pneumococcal conjugate vaccine is reported in reference 22, with multiple carriers being used in order to avoid carrier suppression. The authors predict that there is a maximum load of a carrier protein that can be tolerated in a multivalent conjugate vaccine without giving rise to negative interference. In reference 23 it was reported that pneumococcal conjugate
- 25 vaccines including mixed carrier proteins elicited, in parallel to the anti pneumococcus response, unintentional booster responses to the carriers.
- 30

- In reference 24, an investigation of whether diphtheria and tetanus boosters could be administered with monovalent meningococcal serogroup C conjugates, it was found that titres against the meningococcal conjugate were reduced where the carrier was tetanus toxoid carrier and the patient had received prior immunization with a tetanus-
- 35 containing vaccine.

Finally, reference 25 reports that 'prior exposure to the carrier protein can either enhance or suppress antibody response to polysaccharides administered in saccharide-protein conjugates". The conjugates used in reference 25 used tetanus toxoid or the CRM197 mutant as carrier protein.

- 40 The situation concerning carrier priming and/or suppression is thus confused, and it remains unclear whether any particular conjugate will suffer from carrier suppression or will benefit from a carrier priming enhancement. Meningococcal conjugate vaccines will not be in a position to be integrated into or added to existing pediatric immunization schedules until this issue is addressed. Furthermore, as some
- 45 meningococcal conjugates are to be administered as tetravalent mixtures (i.e. four different conjugates) then the potential for carrier suppression becomes even more of a risk.

In addition to the problem of priming with a carrier having a negative impact on immune responses against saccharide conjugates, the reverse can also occur i.e. immunization with a conjugate can have a negative impact on immune responses against the carrier [26].

5 DISCLOSURE OF THE INVENTION

First aspect of the invention

It has now been found that meningococcal conjugates (on a tetanus toxoid carrier) can be administered to patients even where they have already received the carrier protein, either in the form of a previous immunogen (e.g in a D-T-P or a D-T
10 immunization) or as a previous carrier protein (e.g in a Hib conjugate or pneumococcal conjugate vaccine).

The invention thus provides a method for immunising a human patient against a disease caused by *Neisseria meningitidis*, comprising the step of administering to the human patient a composition that comprises at least two of: (a) a conjugate of (i) the
15 capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; and (d) a conjugate of (i) the capsular saccharide of serogroup Y
20 *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof.

It also provides a method for immunising a human patient against a disease caused
25 by *Neisseria meningitidis*, comprising the step of administering to the human patient a composition that comprises at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid; (c)
30 a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid, wherein the patient has been pre-immunised with (a) a tetanus toxoid and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N. meningitidis* and (ii) a tetanus toxoid.

Furthermore there is provided a use of at least two of: (a) a conjugate of (i) the
35 capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N. meningitidis* and (ii) a tetanus toxoid or derivative thereof; and (d) a conjugate of (i) the capsular saccharide of serogroup Y
40 *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by *Neisseria meningitidis*, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof.

45 There is also provided a use of at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid; (b) a conjugate of (i) the capsular saccharide of serogroup C *N. meningitidis* and (ii) a tetanus toxoid;

- (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid, in the manufacture of a medicament for immunising a human patient against a disease caused by *Neisseria meningitidis*,
 5 wherein the patient has been pre-immunised with (a) a tetanus toxoid and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid.

The meningococcal disease is preferably meningitis, more preferably bacterial meningitis, and most preferably meningococcal meningitis. Thus the invention can be
 10 used to protect against meningococcal infections that cause meningitis.

Where the pre-immunisation antigen is a derivative of a tetanus toxoid (TT) then that derivative preferably remains immunologically cross- reactive with TT, and is preferably fragment C.

The pre-immunised patient

- 15 The patient to be immunised has been pre- immunised with: (a) a tetanus toxoid or derivative thereof, and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *Neisseria meningitidis* and (ii) a tetanus toxoid or derivative thereof. Typical pre-immunisation will have included: a tetanus toxoid antigen, a Hib capsular saccharide conjugate using a tetanus toxoid carrier, and/or a pneumococcal capsular
 20 saccharide conjugate using a tetanus toxoid carrier.

The patient will have received at least one (e.g 1, 2, 3 or more) dose of the pre-immunisation antigen(s), and that dose (or the earliest of multiple doses) will have been administered to the patient at least 0.5, 1, 2, 4 or at least six (e.g 6, 9, 12, 15, 18, 21, 24, 36, 48, 60, 120, 180, 240, 300 or more) months before the immunization
 25 with the meningococcal conjugates according to the invention. In a preferred group of patients, the pre- immunisation took place within 3 years of birth e.g within 2 years of birth, within 1 year of birth, within 6 months of birth, or even within 3 months, 2 months or 1 month of birth.

The patient to be immunised according to the invention will typically be a human. The
 30 human will generally be at least 1 month old e.g at least 2 months old, at least 3 months old, at least 4 months old, at least 6 months old, at least 2 years old, at least 5 years old, at least 11 years old, at least 17 years old, at least 40 years old, at least 55 years old, etc. A preferred set of patients is at least 6 months old. Another preferred set of patients is in the age group 2-55 years old, and another preferred set
 35 of patients is in the age group 11 -55 years old. A further preferred set of patients is less than 11 years old e.g 2-11 years old. In all cases, however, regardless of age, the patient will have been pre- immunised as defined herein.

Where the pre-immunisation antigen is a tetanus toxoid then the patient will typically have received the toxoid as the 'T' antigen in a D-T-P or a D-T pre-immunisation.
 40 Such immunizations are typically given to newborn children at ages 2, 3, and 4 months. Where the immunization includes a pertussis vaccine, that vaccine may be a whole cell or cellular pertussis vaccine ('Pw'), but is preferably an acellular pertussis vaccine ('Pa'). Pre-immunisation Pa vaccines will generally include one, two or three of the following well-known and well-characterised *B.pertussis* antigens: (1) pertussis
 45 toxoid ('PT'), detoxified either by chemical means or by site- directed mutagenesis eg the 9K/129G' mutant [30], (2) filamentous haemagglutinin ('FHA'), (3) pertactin (also known as '69 kiloDalton outer membrane protein'). Acellular pertussis vaccines may

also include agglutininogen 2 and/or agglutininogen 3. The 'D' antigen in a D-T-P pre-immunisation is typically a diphtheria toxoid.

Where the pre-immunisation antigen is a tetanus toxoid then the patient may also or alternatively have received the toxoid as the carrier protein of a protein-saccharide conjugate. Such conjugates include the 'PRP-T' Hib conjugate.

Where the pre-immunisation antigen is tetanus toxoid then the patient will typically have been pre-immunised with a Hib conjugate and/or a multivalent pneumococcal conjugate. Such immunizations are typically given to newborn children at ages 2, 3, and 4 months. Hib conjugates are well known (reference 32). Pneumococcal conjugates may also use a Tetanus toxoid carrier for one or more of the saccharides. The patient may also have been pre-immunised with a serogroup C meningococcal ('MenC') conjugate. MenC conjugates that use tetanus toxoid as a carrier. Preferably, however, the patient has been pre-immunised with Hib and/or pneumococcal conjugate, but not with a MenC conjugate. If the patient has been pre-immunised with a MenC conjugate then the vaccine administered according to the invention may or may not include a serogroup C conjugate.

Tetanus toxoid is a well known and well characterized protein that can be obtained by treating the toxin with an inactivating chemical, such as formalin or formaldehyde.

The result of the pre-immunisation is that the patient's immune system has been exposed to the pre-immunisation antigens. For pre-immunisation with tetanus toxoid (Tt), this generally means that the patient will have raised an anti-Tt antibody response (typically to give an anti-Tt titer >0.01 IU/ml) and will possess memory B and/or T lymphocytes specific for Tt i.e. pre-immunisation with Tt is typically adequate to elicit an anamnestic anti-Tt immune response in the patient. For pre-immunisation where Tt (or derivative) is a carrier for a saccharide within a conjugate then the pre-immunisation will have raised an anti-saccharide response and the patient will possess memory B and/or T lymphocytes specific for the saccharide i.e. the pre-immunisation is typically adequate to elicit an anamnestic anti-saccharide immune response in the patient. The pre-immunisation was preferably adequate to elicit protective immunity in the patient e.g. against tetanus disease.

Thus the patients to be immunised according to the invention are distinct from patients in general, as they are members of a subset of the general population whose immune systems have already mounted an immune response to the pre-immunisation antigens, such that immunization according to the invention with a meningococcal conjugate that includes a tetanus toxoid (or derivative thereof) carrier elicits a different immune response in the subset than in patients who have not previously mounted an immune response to the pre-immunisation antigens. Patients who have been pre-immunised with Tt (or derivative) as the carrier of a conjugate (particularly of a Hib conjugate) are preferred. Particularly preferred patients have been pre-immunised with Tt (or derivative) as the carrier of a conjugate and also with Tt as an unconjugated immunogen.

As well as having been pre-immunised with a tetanus toxoid (or derivative), in conjugated or non-conjugated form, the patient may have been pre-immunised with other antigens. Such antigens include, but are not limited to: pertussis antigen(s) - see above; diphtheria toxoid - see above; *Haemophilus influenzae* type B - see above; hepatitis B surface antigen (HBsAg); poliovirus, such as an inactivated poliovirus vaccine (IPV); *Streptococcus pneumoniae* - see above; influenza virus; BCG; hepatitis A virus antigens; measles virus; mumps virus; rubella virus; varicella

virus; etc. The patient may or may not have been pre-immunised with one or more meningococcal capsular saccharide conjugate(s).

- 5 In some preferred embodiments, at the time when a patient first receives a meningococcal conjugate, they have already been pre-immunised with Tt (or derivative). In other embodiments, a meningococcal conjugate is administered to a patient who has already been pre-immunised with both (i) Tt or a derivative and (ii) a meningococcal conjugate.

The conjugates

- 10 The invention immunises patients with conjugated saccharides. Conjugation is used to enhance the immunogenicity of saccharides, as it converts them from T-independent antigens to T-dependent antigens, thus allowing priming for immunological memory. Conjugation is particularly useful for pediatric vaccines [e.g. ref. 37] and is a well known technique [e.g. reviewed in refs. 38 to 46].

- 15 The composition used according to the invention comprises at least two meningococcal conjugates, wherein each conjugate comprises a tetanus toxoid (or derivative thereof) carrier protein, and the capsular saccharide. The capsular saccharides are chosen from meningococcal serogroups A, C, W135 and Y, such that the compositions include saccharides from 2, 3, or all 4 of these four serogroups. Specific compositions comprise saccharides from: serogroups A & C, serogroups A & W; serogroups A & Y; serogroups C & W135; serogroups C & Y. serogroups W135 & Y.; serogroups A & C & W135; serogroups A & C & Y; serogroups A & W135 & Y.; serogroups C & W135 & Y.; serogroups A & C & W135 & Y. Compositions including saccharides from all four serogroups are most preferred.

- 25 The capsular saccharides of each of these four serogroups are well characterized. The capsular saccharide of serogroup A meningococcus is a homopolymer of (α 1 $\rightarrow$ 6)-linked N-acetyl-D-mannosamine-1-phosphate, with partial O-acetylation in the C3 and C4 positions. The acetyl groups can be replaced with blocking groups to prevent hydrolysis [47], and such modified saccharides are still serogroup A saccharides within the meaning of the present invention. The serogroup C capsular
30 saccharide is a homopolymer of (α 2 $\rightarrow$ 9)-linked sialic acid (N-acetyl neuraminic acid, or 'NeuNAc'). Most serogroup C strains have O-acetyl groups at C-7 and/or C-8 of the sialic acid residues, but about 15% of clinical isolates lack these O-acetyl groups [48,49]. The saccharide structure is written as $\rightarrow$ 9)-Neu p NAc 7/8 OA(α 2 $\rightarrow$. The serogroup W135 saccharide is a polymer of sialic acid galactose disaccharide units.
35 Like the serogroup C saccharide, it has variable O-acetylation, but at sialic acid 7 and 9 positions [50]. The structure is written as: $\rightarrow$ 4)-D-Neu p5Ac(7/9OAc)- α -(2 $\rightarrow$ 6) D-Gal- α -(1 $\rightarrow$. The serogroup Y saccharide is similar to the serogroup W135 saccharide, except that the disaccharide repeating unit includes glucose instead of galactose. Like serogroup W135, it has variable O-acetylation at sialic acid 7 and 9
40 positions [50]. The serogroup Y structure is written as: $\rightarrow$ 4)-D-Neu p5Ac(7/9OAc)- α -(2 $\rightarrow$ 6) D-Glc- α -(1 $\rightarrow$.

- 45 The saccharides used according to the invention may be O-acetylated as described above (e.g. with the same O-acetylation pattern as seen in native capsular saccharides), or they may be partially or totally de-O-acetylated at one or more positions of the saccharide rings, or they may be hyper-O-acetylated relative to the native capsular saccharides.

- The saccharides used according to the invention may be shorter than the native capsular saccharides seen in bacteria. Thus the saccharides may be depolymerised, with depolymerisation occurring after purification but before conjugation. Depolymerisation reduces the chain length of the saccharides. One depolymerisation method involves the use of hydrogen peroxide [9]. Hydrogen peroxide is added to a saccharide (e.g. to give a final H₂O₂ concentration of 1%), and the mixture is then incubated (e.g. at about 55°C) until a desired chain length reduction has been achieved. Another depolymerisation method involves acid hydrolysis [10]. Other depolymerisation methods are known to the skilled person. The saccharides used to prepare conjugates for use according to the invention may be obtainable by any of these depolymerisation methods. Depolymerisation can be used in order to provide an optimum chain length for immunogenicity and/or to reduce chain length for physical manageability of the saccharides.
- Typical carrier proteins for use in conjugates are bacterial toxins or toxoids, such as diphtheria toxin (or its CRM97 mutant) and tetanus toxin. Other known carrier proteins include the *N.meningitidis* outer membrane protein, synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, artificial proteins comprising multiple human CD4+ T cell epitopes from various pathogen- derived antigens, protein D from non-typeable *H.influenzae*, pneumococcal surface protein PspA, iron-uptake proteins, toxin A or B from *C.difficile*, etc. According to the invention, however, the meningococcal conjugates include a tetanus toxoid (or derivative thereof, such as fragment C) carrier protein. Covalent conjugation is preferred.
- It is possible to use more than one carrier protein in the compositions. Thus different carrier proteins can be used for different serogroups e.g. serogroup A saccharides might be conjugated to tetanus toxoid while serogroup C saccharides might be conjugated to diphtheria toxoid. It is also possible to use more than one carrier protein for a particular saccharide antigen e.g. serogroup A saccharides might be in two groups, with some conjugated to tetanus toxoid and others conjugated to diphtheria toxoid. In general, however, it is preferred to use the same carrier protein for all meningococcal saccharides in the composition, and more preferably for all saccharides (i.e. including any non-meningococcal conjugates that may be present). It is preferred that compositions/medicaments of this aspect of the invention do not include any diphtheria tetanus toxoid or CRM197 carrier protein.
- A single carrier protein might carry more than one saccharide antigen [51]. For example, a single carrier protein might have conjugated to it saccharides from serogroups A and C. To achieve this goal, saccharides can be mixed prior to the conjugation reaction. In general, however, it is preferred to have separate conjugates for each serogroup. Conjugates are preferably mixed to give substantially a 1:1:1:1 ratio (measured as mass of saccharide) e.g. the mass of each serogroup's saccharide is within +10% of each other. A typical quantity of meningococcal antigen per serogroup in a composition is between 1 µg and 20 µg e.g. between 2 and 10 µg per serogroup, or about 4 or 5 µg. As an alternative to a 1:1:1:1 ratio, a double serogroup A dose may be used (2:1: 1:1).
- Conjugates with a saccharide:protein ratio (w/w) of between 1:15 (i.e. excess protein) and 15:1 (i.e. excess saccharide), preferably between 1:10 and 10:1, more preferably between 1:5 and 5:1, are preferred. Excess carrier protein may be used for instance 1:3.

Conjugates may be used in conjunction with free carrier protein [52]. When a given carrier protein is present in both free and conjugated form in a composition of the invention, however, the unconjugated form is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight. Similarly, unconjugated saccharide is preferably no more than 15% by weight of the total amount of saccharide.

Any suitable conjugation reaction can be used, with any suitable linker where necessary.

The saccharide will typically be activated or functionalised prior to conjugation. Activation may involve, for example, cyanylating reagents such as CDAP (e.g. 1-cyano-4-dimethylamino pyridinium tetrafluoroborate [53, 54, etc.]). Other suitable techniques use carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S- NHS, EDC, TSTU; see also the introduction to reference 44).

Linkages via a linker group may be made using any known procedure, for example, the procedures described in references 55 and 56. One type of linkage involves reductive amination of the polysaccharide, coupling the resulting amino group with one end of an adipic acid linker group, and then coupling a protein to the other end of the adipic acid linker group [42, 57, 58]. Other linkers include B-propionamido [59], nitrophenyl- ethylamine [60], haloacyl halides [61], glycosidic linkages [62], 6-aminocaproic acid [63], ADH [64], C4 to C12 moieties [65] etc. As an alternative to using a linker, direct linkage can be used. Direct linkages to the protein may comprise oxidation of the polysaccharide followed by reductive amination with the protein, as described in, for example, references 66 and 67.

A process involving the introduction of amino groups into the saccharide (e.g. by replacing terminal =O groups with -NH₂) followed by derivatisation with an adipic diester (e.g. adipic acid N- hydroxysuccinimido diester) and reaction with carrier protein may be done.

In one conjugation method, a saccharide is reacted with adipic acid dihydrazide. For serogroup A, carbodiimide may also be added at this stage. After a reaction period, sodium cyanoborohydride is added. Derivatized saccharide can then be prepared e.g. by ultrafiltration. The derivatized saccharide is then mixed with carrier protein (e.g. with a tetanus toxoid), and carbodiimide is added. After a reaction period, the conjugate can be recovered. Further details of this conjugation method can be found in reference 10. Conjugates obtainable by this method may be used according to the invention e.g. conjugates comprising a tetanus toxoid carrier and an adipic acid linker. Conjugates are preferably prepared separately and then mixed. After mixing, the concentration of the mixed conjugates can be adjusted e.g. with sterile pyrogen-free, phosphate-buffered saline. Each conjugate, before mixing, preferably contains no more than 15 µg of carrier.

The result of administering meningococcal conjugates according to the invention is preferably that, for each administered serogroup, the patient raises a serum bactericidal antibody (SBA) response; with the increase in SBA titre (compared to the pre-immunised patient before receiving the mixed meningococcal conjugates) being at least 4-fold, and preferably at least 8-fold. The SBA test is a standard correlate for meningococcal protection. Further details of serologic correlates for meningococcal vaccines are given in reference 68.

Further antigenic components of compositions used according to the invention

In addition to meningococcal conjugates, compositions used according to the invention may optionally include 1, 2 or 3 of the following further antigens:

- 5 1. A conjugated capsular saccharide from *S. pneumoniae* [e.g chapter 23 of ref.32; refs. 69-71].

It is preferred to include saccharides from more than one serotype of *S. pneumoniae*. For example; mixtures of polysaccharides from 23 different serotype are known, as are conjugate vaccines with polysaccharides from between 5 and 11 different serotypes [72]. For example, PreVNar™ [31] contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) with each saccharide individually conjugated to CRM197 by reductive amination, with 2µg of each saccharide per 0.5ml dose (4µg of serotype 6B), and with conjugates adsorbed on an aluminium phosphate adjuvant. Where pneumococcal conjugates are included in a compositions for use with the invention, the composition preferably includes at least serotypes 6B, 14, 19F and 15 23F. One or more serotypes may be conjugated to tetanus toxoid.

2. A conjugated capsular saccharide from *H.influenzae* B [e.g chapter 14 of ref.32].

The carrier protein for the conjugate may be CRM197, Dt, a tetanus toxoid or an outer membrane complex of *N.meningitidis*. The saccharide moiety of the conjugate may be a polysaccharide (e.g full-length polyribosylribitol phosphate (PRP)), but can 20 also have undergone depolymerisation of the capsular polysaccharides to form oligosaccharides (e.g. MW from 1 to 5 kDa). One Hib conjugate comprises an oligosaccharide covalently linked to CRM197 via an adipic acid linker [73,74]. Another uses Tetanus toxoid instead. Administration of the Hib antigen preferably results in an anti-PRP antibody concentration of >0.15 µg/ml, and more preferably 25 >1µg/ml. Where a composition includes a Hib saccharide antigen, it preferably does not also include an aluminium hydroxide adjuvant. If the composition includes an aluminium phosphate adjuvant then the Hib antigen may be adsorbed to the adjuvant [75] or it may be non-adsorbed [27]. Prevention of adsorption can be achieved by selecting the correct pH during antigen/adjuvant mixing, an adjuvant with an 30 appropriate point of zero charge, and an appropriate order of mixing for the various different antigens in a composition [76].

3. A protein antigen from *Neisseria meningitidis* serogroup B [e.g ref. 77].

The composition may comprise one or more of these further antigens. It may be an outer membrane vesicle preparation.

- 35 Such antigens may or may not be adsorbed to an aluminium salt.

If meningococcal conjugates are being administered in a series of doses then none, some or all of the doses may include these extra antigens.

Compositions containing the meningococcal conjugates preferably do not include diphtheria toxoid nor CRM197.

- 40 They preferably do not include pertussis antigens. They preferably do not include hepatitis B virus surface antigen. They preferably do not include poliovirus. A composition preferably contains no more than 50 µg of tetanus toxoid per

meningococcal conjugate, and more preferably no more than 50 µg of tetanus toxoid for all meningococcal conjugates combined.

Second aspect of the invention

- 5 As reported above, pneumococcal vaccination now tends to occur concomitantly with the first primary immunisation vaccination (around 2 months of age). The inventors believe that pre-immunisation with one or more carriers used for the pneumococcal conjugate vaccine may be useful.

- 10 This in a further aspect of the invention there is provided a method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to a diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with
15 (a) a diphtheria toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

- There is also provided a method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the
20 human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to tetanus toxoid or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus
25 and (ii) a tetanus toxoid or derivative thereof.

- In one embodiment of the invention there is provided a method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide
30 serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof and at least one of which is conjugated to diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or
35 derivative thereof and (c) a diphtheria toxoid or derivative thereof and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

- Corresponding uses are also provided: the use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus,
40 at least one of which conjugated to a diphtheria toxoid or CRM197 or a derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a diphtheria toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria
45 toxoid or CRM197 or derivative thereof; the use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to a tetanus toxoid or a derivative

thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof; and the use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof and at least one of which is conjugated to diphtheria toxoid or CRM197 or a derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof and (c) a diphtheria toxoid or derivative thereof and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

Where the pre-immunisation antigen is a derivative of a diphtheria toxoid then that derivative preferably remains immunologically cross- reactive with Dt, and is preferably CRM197. Where the pre-immunisation antigen is a derivative of a tetanus toxoid then that derivative preferably remains immunologically cross- reactive with Tt, and is preferably fragment C.

The pre-immunised patient

The patient to be immunised has been pre- immunised with: (a) a diphtheria toxoid or derivative thereof, and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or derivative thereof, and/or c) a tetanus toxoid or derivative thereof, and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof,. Typical pre-immunisation will have included: a diphtheria toxoid antigen, a tetanus toxoid antigen, a Hib capsular saccharide conjugate using a diphtheria toxoid or CRM197 carrier or tetanus toxoid carrier, and/or a meningococcal capsular saccharide conjugate using a diphtheria toxoid or CRM197 carrier or tetanus toxoid.

The patient will have received at least one (e.g 1, 2, 3 or more) dose of the pre-immunisation antigen(s), and that dose (or the earliest of multiple doses) will have been administered to the patient at least 0.5, 1, 2, 4 or at least six (e.g 6, 9, 12, 15, 18, 21, 24, 36, 48, 60, 120, 180, 240, 300 or more) months before the immunization with the meningococcal conjugates according to the invention. In a preferred group of patients, the pre- immunisation took place within 3 years of birth e.g within 2 years of birth, within 1 year of birth, within 6 months of birth, or even within 3 months, 2 months or 1 month of birth.

The patient to be immunised according to the invention will typically be a human. The human will generally be at least 1 month old e.g at least 2 months old, at least 3 months old, at least 4 months old, at least 6 months old, at least 2 years old, at least 5 years old, at least 11 years old, at least 17 years old, at least 40 years old, at least 55 years old, etc. A preferred set of patients is at least 6 months old. Another preferred set of patients is in the age group 2-55 years old, and another preferred set of patients is in the age group 11 -55 years old. A further preferred set of patients is less than 11 years old e.g 2-11 years old. In all cases, however, regardless of age, the patient will have been pre- immunised as defined herein.

Where the pre-immunisation antigen is a diphtheria toxoid or tetanus toxoid then the patient will typically have received the toxoid as the 'D' or 'T' antigen, respectively, in a D-T-P or a D-T pre-immunisation. Such immunizations are typically given to newborn children at ages 2, 3, and 4 months. Where the immunization includes a pertussis vaccine, that vaccine may be a whole cell or cellular pertussis vaccine ('Pw'), but is preferably an acellular pertussis vaccine ('Pa'). Pre-immunisation Pa vaccines will generally include one, two or three of the following well-known and well-characterised B.pertussis antigens: (1) pertussis toxoid ('PT'), detoxified either by chemical means or by site-directed mutagenesis e.g. the '9K/129G' mutant [30], (2) filamentous haemagglutinin ('FHA'), (3) pertactin (also known as '69 kiloDalton outer membrane protein'). Acellular pertussis vaccines may also include agglutinin 2 and/or agglutinin 3.

Where the pre-immunisation antigen is a diphtheria toxoid or tetanus toxoid then the patient may also or alternatively have received the toxoid as the carrier protein of a protein-saccharide conjugate. Such conjugates include the 'PRP-D' or 'PRP-T' Hib conjugates [see Table 14-7 of ref.32] e.g. the ProHIBIT™ product.

Where the pre-immunisation antigen is CRM197 then the patient will typically have been pre-immunised with a Hib conjugate and/or a multivalent pneumococcal conjugate. Such immunizations are typically given to newborn children at ages 2, 3, and 4 months. Hib conjugates that use a CRM197 carrier include the 'HbOC' conjugates [Table 14-7 of ref. 32] e.g. the HibTITER™ product. Pneumococcal conjugates that use a CRM197 carrier include the 7-valent PCV7 mixtures e.g. the Prevnar™ vaccine [31]. The patient may also have been pre-immunised with a serogroup C meningococcal ('MenC') conjugate. MenC conjugates that use CRM197 carrier include Meninvact™/Menjugate™ [5] and Meningitec™. Preferably, however, the patient has been pre-immunised with Hib and/or pneumococcal conjugate, but not with a MenC conjugate. If the patient has been pre-immunised with a MenC conjugate then the vaccine administered according to the invention may or may not include a serogroup C conjugate.

Diphtheria and tetanus toxoids are well known and well characterized proteins [e.g. see chapter 13 of ref. 32] that can be obtained by treating the toxin with an inactivating chemical, such as formalin or formaldehyde. CRM197 is also well known and well characterized [33-36], and has been widely used as a carrier in conjugated saccharide vaccines.

CRM197 and Dt share many carrier epitopes.

The result of the pre-immunisation is that the patient's immune system has been exposed to the pre-immunisation antigens. For pre-immunisation with diphtheria toxoid (Dt) or tetanus toxoid, this generally means that the patient will have raised an anti-Dt or -Tt antibody response (typically to give an anti-Dt titer >0.01 IU/ml) and will possess memory B and/or T lymphocytes specific for Dt or Tt i.e. pre-immunisation with Dt or Tt is typically adequate to elicit an anamnestic anti-Dt or -Tt immune response in the patient. For pre-immunisation where Dt or Tt (or derivative) is a carrier for a saccharide within a conjugate then the pre-immunisation will have raised an anti-saccharide response and the patient will possess memory B and/or T lymphocytes specific for the saccharide i.e. the pre-immunisation is typically adequate to elicit an anamnestic anti-saccharide immune response in the patient. The pre-immunisation was preferably adequate to elicit protective immunity in the patient e.g. against diphtheria or tetanus disease.

Thus the patients to be immunised according to the invention are distinct from patients in general, as they are members of a subset of the general population whose immune systems have already mounted an immune response to the pre-immunisation antigens, such that immunization according to the invention with a pneumococcal conjugate that includes a diphtheria toxoid and/or tetanus toxoid (or derivative thereof) carrier elicits a different immune response in the subset than in patients who have not previously mounted an immune response to the pre-immunisation antigens. Patients who have been pre-immunised with Dt and/or Tt (or derivative) as the carrier of a conjugate (particularly of a Hib conjugate) are preferred. Particularly preferred patients have been pre-immunised with Dt and/or Tt (or derivative) as the carrier of a conjugate and also with Dt and/or Tt as an unconjugated immunogen.

As well as having been pre-immunised with a diphtheria toxoid and/or tetanus toxoid (or derivative), in conjugated or non-conjugated form, the patient may have been pre-immunised with other antigens. Such antigens include, but are not limited to: pertussis antigen(s) - see above; *Haemophilus influenzae* type B - see above; hepatitis B surface antigen (HBsAg); poliovirus, such as an inactivated poliovirus vaccine (IPV); meningococcal capsular saccharide conjugates - see above; influenza virus; BCG; hepatitis A virus antigens; measles virus; mumps virus; rubella virus; varicella virus; etc. The patient may or may not have been pre-immunised with one or more pneumococcal capsular saccharide conjugate(s).

In some preferred embodiments, at the time when a patient first receives a pneumococcal conjugate, they have already been pre-immunised with Dt and/or Tt (or derivative). In other embodiments, a pneumococcal conjugate is administered to a patient who has already been pre-immunised with both (i) Dt and/or Tt or a derivative and (ii) a pneumococcal conjugate.

The conjugates

The invention immunises patients with conjugated saccharides. Conjugation is used to enhance the immunogenicity of saccharides, as it converts them from T-independent antigens to T-dependent antigens, thus allowing priming for immunological memory. Conjugation is particularly useful for pediatric vaccines [e.g. ref. 37] and is a well known technique [e.g. reviewed in refs. 38 to 46].

Typically the *Streptococcus pneumoniae* compositions/medicaments of the invention (or in any of the immunogenic compositions of the invention described herein) will comprise conjugated saccharide antigens, wherein the saccharides are derived from at least four serotypes of pneumococcus chosen from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. Preferably the four serotypes include 6B, 14, 19F and 23F. More preferably, at least 7 serotypes are included in the composition, for example those derived from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. More preferably still more than 7 serotypes are included in the composition, for instance at least 10, 11, 12, 13 or 14 serotypes. For example the composition in one embodiment includes 10 or 11 capsular saccharides derived from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, and optionally 3 (all conjugated). In a preferred embodiment of the invention at least 13 saccharide antigens (preferably all conjugated) are included, although further saccharide antigens, for example 23 valent (such as serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), are also contemplated by the invention. For example, mixtures of polysaccharides from 23 different serotypes are widely used, as are conjugate

- vaccines with polysaccharides from between 5 and 11 different serotypes [72]. For example, Prevnar™ [31] contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) with each saccharide individually conjugated to CRM197 by reductive amination, with 2µg of each saccharide per 0.5ml dose (4µg of serotype 6B), and with conjugates adsorbed on an aluminium phosphate adjuvant. The composition preferably includes at least serotypes 6B, 14, 19F and 23F.

The capsular saccharides of each of these serotypes are well known. Meningococcal saccharides are also well known (see above for description of the saccharides and envisaged combinations of serogroup saccharides of the invention).

- The saccharides used according to the invention may be O-acetylated as (e.g with the same O-acetylation pattern as seen in native capsular saccharides), or they may be partially or totally de-O- acetylated at one or more positions of the saccharide rings, or they may be hyper-O-acetylated relative to the native capsular saccharides.

- The saccharides used according to the invention may be shorter than the native capsular saccharides seen in bacteria. Thus the saccharides may be depolymerised, with depolymerisation occurring after purification but before conjugation. Depolymerisation reduces the chain length of the saccharides. A possible depolymerisation method involves the use of hydrogen peroxide [9]. Hydrogen peroxide is added to a saccharide (e.g to give a final H₂O₂ concentration of 1%), and the mixture is then incubated (e.g at about 55°C) until a desired chain length reduction has been achieved. Another depolymerisation method involves acid hydrolysis [10]. Other depolymerisation methods are known to the skilled person. The saccharides used to prepare conjugates for use according to the invention may be obtainable by any of these depolymerisation methods. Depolymerisation can be used in order to provide an optimum chain length for immunogenicity and/or to reduce chain length for physical manageability of the saccharides.

- Typical carrier proteins for use in conjugates are bacterial toxins or toxoids, such as diphtheria toxin (or its CRM97 mutant) and tetanus toxin. Other known carrier proteins include the *N.meningitidis* outer membrane protein, synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, artificial proteins comprising multiple human CD4+ T cell epitopes from various pathogen- derived antigens, protein D from non-typeable *H.influenzae*, pneumococcal surface protein PspA, iron-uptake proteins, toxin A or B from *C.difficile*, etc. According to the invention, however, the pneumococcal conjugates include a diphtheria toxoid and/or tetanus toxoid (or derivative thereof, such as CRM197) carrier protein. Covalent conjugation is preferred.

- It is possible to use more than one carrier protein in the compositions. Thus different carrier proteins can be used for different serotypes e.g serotype 7F might be conjugated to protein D while serotype 18C saccharide might be conjugated to tetanus toxoid. It is also possible to use more than one carrier protein for a particular saccharide antigen e.g serotype 7F saccharide might be in two groups, with some conjugated to CRM197 and some conjugated to protein D. In general, however, it is preferred to use the same carrier protein for all or the majority of the pneumococcal saccharides in the composition. The saccharide composition can be conjugated to Dt and Tt, Dt and Crm197, CRM197 and Tt, and Dt, CRM197 and Tt. Protein D may be added to any of these lists of carriers for conjugating (the majority) of the saccharides to. In one embodiment only 1 serotype is conjugated to Dt or CRM197 and/or only one conjugated to Tt.

A single carrier protein might carry more than one saccharide antigen [51]. For example, a single carrier protein might have conjugated to it capsular saccharides from serotypes 7F and 18C. To achieve this goal, saccharides can be mixed prior to the conjugation reaction. In general, however, it is preferred to have separate
 5 conjugates for each serotype. Conjugates may be mixed to give substantially a 1:1:1:1 ratio (measured as mass of saccharide) e.g. the mass of each serogroup's saccharide is within +10% of each other. A typical quantity of meningococcal antigen per serogroup in a composition is between 1 µg and 20 µg e.g. between 2 and 10 µg per serotype.

10 Conjugates with a saccharide:protein ratio (w/w) of between 1:15 (i.e. excess protein) and 15:1 (i.e. excess saccharide), preferably between 1:10 and 10:1, more preferably between 1:5 and 5:1, may be used.

Conjugates may be used in conjunction with free carrier protein [52]. When a given carrier protein is present in both free and conjugated form in a composition of the
 15 invention, however, the unconjugated form is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight. Similarly, unconjugated saccharide is preferably no more than 15% by weight of the total amount of saccharide.

Any suitable conjugation reaction can be used, with any suitable linker where
 20 necessary (see above and references therein for typical conjugation reactions which may be used in the present aspect of the invention). If a linker is employed, in one embodiment it is ADH (adipic acid dihydrazide). Conjugates obtainable by such methods are preferred conjugates for use according to the invention e.g. conjugates comprising a diphtheria toxoid and/or tetanus toxoid carrier (and optionally an adipic
 25 acid linker). Conjugates are preferably prepared separately and then mixed. After mixing, the concentration of the mixed conjugates can be adjusted e.g. with sterile pyrogen-free, phosphate-buffered saline. Each conjugate, before mixing, preferably contains no more than 15 µg of carrier.

Further antigenic components of compositions used according to the invention

30 In addition to pneumococcal conjugates, compositions used according to the invention may optionally include 1, 2 or 3 of the following further antigens:

1. A conjugated capsular saccharide from *N. meningitidis*; refs. 69-71; see above].

In one embodiment the compositions/medicaments of the invention do not comprise any meningococcal saccharide conjugates. Preferably a tetanus toxoid is present as a
 35 carrier.

2. A conjugated capsular saccharide from *H. influenzae* B [e.g. chapter 14 of ref.32].

The carrier protein for the conjugate may be CRM197, Dt, a tetanus toxoid or an outer membrane complex of *N. meningitidis*. The saccharide moiety of the conjugate may be a polysaccharide (e.g. full-length polyribosylribitol phosphate (PRP)), but it is
 40 preferred to depolymerise the capsular polysaccharides to form oligosaccharides (e.g. MW from 1 to 5 kDa). A preferred Hib conjugate comprises an oligosaccharide covalently linked to CRM197 or tetanus toxoid via an adipic acid linker [73,74]. Administration of the Hib antigen preferably results in an anti-PRP antibody concentration of >0.15 µg/ml, and more preferably >1 µg/ml. Where a composition
 45 includes a Hib saccharide antigen, it preferably does not also include an aluminium

- hydroxide adjuvant. If the composition includes an aluminium phosphate adjuvant then the Hib antigen may be adsorbed to the adjuvant [75] or it may be non-adsorbed [27]. Prevention of adsorption can be achieved by selecting the correct pH during antigen/adjuvant mixing, an adjuvant with an appropriate point of zero charge, and an appropriate order of mixing for the various different antigens in a composition [76].

3. A protein antigen from *Neisseria meningitidis* serogroup B [e.g. ref. 77].

The composition may comprise one or more of these further antigens. These can be in the form of isolated outer membrane proteins, or in the form of a subunit antigen preparation.

- 10 Such antigens may or may not be adsorbed to an aluminium salt.

If pneumococcal conjugates are being administered in a series of doses then none, some or all of the doses may include these extra antigens.

Compositions containing the pneumococcal conjugates in one embodiment do not include meningococcal capsular saccharide conjugates.

- 15 In one embodiment they do not include pertussis antigens. In one embodiment they do not include hepatitis B virus surface antigen. In one embodiment they do not include poliovirus. A composition preferably contains no more than 50 µg of diphtheria toxoid / CRM197 per pneumococcal conjugate, and more preferably no more than 50 µg of diphtheria toxoid / CRM197 for all pneumococcal conjugates combined. A composition preferably contains no more than 50 µg of tetanus toxoid per pneumococcal conjugate, and more preferably no more than 50 µg of tetanus toxoid for all pneumococcal conjugates combined.

Third aspect of the invention

- 25 In a third aspect of the invention, the inventors have devised ways to administer various vaccines which use tetanus toxoid and/or DT (and/or CRM197). The written description of the first and second aspects of the invention above and claims 45 onward is also relevant and incorporated by reference to this third aspect of the invention.
- 30 There is further provided a method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

	Visit 1	Visit 2	Visit 3	Visit 4
DTP	X		X	
Strep		X		X
MenC		X		X

- 35 wherein the visit to the medical practitioner all occur in the first 8 months of life, wherein there is at least 2 weeks between each consecutive visit,

- wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
 5 wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,
 wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

10

- In a further aspect there is provided a method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

15

	Visit 1	Visit 2	Visit 3	Visit 4
DTP	X	X	X	
Strep	X		X	
MenC		X		Optionally X

- wherein the visit to the medical practitioner all occur in the first 8 months of life,
 wherein there is at least 2 weeks between each consecutive visit,
 wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
 20 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
 wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,
 25 wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

- In a further embodiment there is provided a method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

30

	Visit 1	Visit 2	Visit 3
DTP	X	X	X
Strep	X	X	
MenC		X	X

- wherein the visit to the medical practitioner all occur in the first 8 months of life,
 wherein there is at least 2 weeks between each consecutive visit,
 wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine
 40 comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
 wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,

wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

5 General considerations of the aspects of the invention

The vaccine composition

The composition used according to the invention will typically include a pharmaceutically acceptable carrier. Such carriers include any carrier that does not itself induce the production of antibodies; harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art.

The vaccines may also contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate-buffered physiologic saline is a typical carrier. A thorough discussion of pharmaceutically acceptable carriers and excipients is available in reference 78.

Compositions used according to the invention may include an antimicrobial, particularly if packaged in a multiple dose format.

Compositions used according to the invention may comprise detergent e.g. a Tween (polysorbate), such as Tween 80. Detergents are generally present at low levels e.g. <0.01%.

Compositions used according to the invention may include sodium salts (e.g. sodium chloride and/or sodium phosphate). These can be used for tonicity. A concentration of 10 ± 2 mg/ml NaCl is typical e.g. about 8.8 mg/ml. A concentration of 1.2 mg/ml sodium phosphate is typical.

Compositions used according to the invention will generally include a buffer e.g. a phosphate buffer.

Compositions used according to the invention may comprise a sugar alcohol (e.g. mannitol) or a disaccharide (e.g. sucrose or trehalose) e.g. at about 15-30 mg/ml (e.g. 25 mg/ml), particularly if they are to be lyophilised or if they include material which has been reconstituted from lyophilised material. Certain compositions, however, may not be lyophilised i.e. meningococcal or pneumococcal conjugates might be in aqueous form, from the packaging stage to the administration stage. Compositions will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, pulmonary or other mucosal administration. Intramuscular administration (e.g. to the thigh or the upper arm) is preferred. Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used. A typical intramuscular dose is 0.5 ml.

Meningococcal or pneumococcal conjugates from multiple serogroups / serotypes are administered in admixture within a single composition. The composition may be administered as a single dose, or may be administered more than once in a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. A primary dose schedule may be followed by a booster dose schedule of the meningococcal or pneumococcal conjugates. Suitable timing between priming doses (e.g. between 4-16 weeks), and between priming and boosting, can be routinely determined. The conjugates may conveniently be administered at the same time as other vaccines e.g. at the same time as a D-T-P vaccine, or at the same time as a pneumococcal or meningococcal conjugate vaccine, or at the same time as an influenza vaccine, or at the same time as a MMR or MMRV vaccine. These vaccines will; generally be administered separately but during the same visit to the doctor.

Bacterial infections can affect various areas of the body and so compositions may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilised composition). The composition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition be prepared for oral administration e.g. as a tablet or capsule, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration e.g. as spray, drops, gel or powder [e.g. refs 79 & 80]. In general, however, the meningococcal or pneumococcal conjugates are formulated for intramuscular injection.

Compositions used according to the invention may or may not include a vaccine adjuvant. Adjuvants which may be used in compositions of the invention include, but are not limited to:

A. Mineral-containing compositions Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminium salts and calcium salts. The invention includes mineral salts such as hydroxides (e.g. oxyhydroxides), phosphates, sulphates, etc. [e.g. see chapters 8 & 9 of ref. 81], or mixtures of different mineral compounds, with the compounds taking any suitable form (e.g. gel, crystalline, amorphous, etc.), and with adsorption being preferred. The mineral containing compositions may also be formulated as a particle of metal salt [82].

Aluminium phosphates may be employed in the compositions of the invention, and a typical adjuvant is amorphous aluminium hydroxyphosphate with PO₄/Al molar ratio between 0.84 and 0.92, included at about 0.6mg Al³⁺/ml.

Adsorption with a low dose of aluminium phosphate may be used e.g. between 50 and 100 µg Al³⁺ per conjugate per dose. Where a composition includes conjugates from multiple bacterial species then not all conjugates need to be adsorbed. ;

B. Oil Emulsions Oil emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59 [Chapter 10 of ref. 81, see also ref. 83] (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer). Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) may also be used.

C. Saponin Formulations [chapter 22 of rep 81]

Saponin formulations may also be used as adjuvants in the invention. Saponins are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species.

- 5 Saponin from the bark of the *Quillaia saponaria* Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from *Smilax ornata* (sarsapilla), *Gypsophilla paniculata* (brides veil), and *Saponaria officinalis* (soap; root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. QS21 is marketed as Stimulon™.
- 10 Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Preferably, the saponin is QS21. A method of production of QS21 is disclosed in ref. 84.

Saponin formulations may also comprise a sterol, such as cholesterol [85].

- 15 Combinations of saponins and cholesterol can be used to form unique particles called immunostimulating complexes (ISCOMs) [chapter 23 of ref. 81]. ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of QuilA, QHA & QHC. ISCOMs are further described
- 20 in refs. 85-87. Optionally, the ISCOMS may be devoid of additional detergent [88].

A review of the development of saponin based adjuvants can be found in refs. 89 & 90.

D. Virosomes and virus-like particles

- 25 Virosomes and virus-like particles (VLPs) can also be used as adjuvants in the invention. These structures generally contain one or more proteins from a virus optionally combined or formulated with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome. The viral proteins may be recombinantly produced or isolated from whole viruses. These viral proteins suitable for use in virosomes or VLPs include proteins
- 30 derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, QJ3-phage (such as coat proteins), GA-I phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein pi). VLPs are discussed further in refs.
- 35 91-96. Virosomes are discussed further in, for example, ref. 97.

E. Bacterial or microbial derivatives

- Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as non-toxic derivatives of enterobacterial lipopolysaccharide (LPS), Lipid A derivatives, immunostimulatory oligonucleotides and ADP-ribosylating toxins and
- 40 detoxified derivatives thereof.

- Non-toxic derivatives of LPS include monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL). 3dMPL is a mixture of 3 de-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. A preferred "small particle" form of 3 De-O-acylated monophosphoryl lipid A is disclosed in ref. 98. Such "small particles" of
- 45 3dMPL are small enough to be sterile filtered through a 0.22 µm membrane [98].

Other non-toxic LPS derivatives Include monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g RC-529 [99,100].

Lipid A derivatives include derivatives of lipid A from *Escherichia coli* such as OM-174. OM-174 is described for example in refs. 101 & 102.

- 5 Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention include nucleotide; sequences containing a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked by a phosphate bond to a guanosine). Double-stranded RNAs and oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be immunostimulatory.
- 10 The CpG's can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or single- stranded. References 103, 104 and 105 disclose possible analog substitutions e.g replacement of guanosine with 2'-deoxy-7-deazaguanosine. The adjuvant effect of CpG oligonucleotides is further discussed in refs. 106-111.
- 15 The CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT [112]. The CpG sequence may be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it may be more specific for inducing a B cell response, such as a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in refs. 113-115. Preferably, the CpG is a CpG-A ODN.
- 20 Preferably, the CpG oligonucleotide is constructed so that the 5' end is accessible for receptor recognition. Optionally, two CpG oligonucleotide sequences may be attached at their 3' ends to form "immunomers". See, for example, refs. 112 & 116-118.
- 25 Bacterial ADP-ribosylating toxins and detoxified derivatives thereof may be used as adjuvants in the invention. Preferably, the protein is derived from *E. coli* (*E. coli* heat labile enterotoxin "LT"), cholera ("CT"), or pertussis ("PT"). The use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in ref. 119 and as parenteral adjuvants in ref. 120. The toxin or toxoid is preferably in the form of a holotoxin, comprising both A and B subunits. Preferably, the A subunit contains a detoxifying mutation; preferably the B subunit is not mutated. Preferably, the adjuvant is a detoxified LT mutant such as LT-K63, LT-R72, and LT- G192. The use of ADP-ribosylating toxins and I detoxified derivatives thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in refs. 121-128. Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in ref. 129, specifically incorporated herein by reference in its entirety.
- 30
- 35

- F. Human immunomodulators Human immunomodulators suitable for use as adjuvants in the invention include cytokines, such as interleukins (e.g IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 [130], etc.) [131], interferons (e.g interferon- γ), macrophage colony stimulating factor, and tumor necrosis factor.
- 40

- G. Bioadhesives and Mucoadhesives Bioadhesives and mucoadhesives may also be used as adjuvants in the invention. Suitable bioadhesives include esterified hyaluronic acid microspheres [132] or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrrolidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof may also be used as adjuvants in the invention [133].
- 45

H. Microparticles

Microparticles may also be used as adjuvants in the invention. Microparticles (i.e. a particle of 100nm to 150nm in diameter, more preferably 200nm to 30µm in diameter, and most preferably 500nm to 10µm in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(α -hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.), with poly(lactide-co-glycolide) are preferred, optionally treated to have a negatively-charged surface (e.g with SDS) or a positively-charged surface (e.g with a cationic detergent, such as CTAB).

I. Liposomes (Chapters 13 & 14 of ref 81)

Examples of liposome formulations suitable for use as adjuvants are described in refs. 134-136.

J. Polyoxyethylene ether and polyoxyethylene ester formulations

Adjuvants suitable for use in the invention include polyoxyethylene ethers and polyoxyethylene esters [137]. Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol [138] as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol [139]. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.

L. Muramylpeptides

Examples of muramyl peptides suitable for use as adjuvants in the invention include N-acetyl muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).

K Polyphosphazene (PCPP) :

PCPP formulations are described, for example, in refs. 140 and 141.

M. Imidazoquinolone Compounds.

Examples of imidazoquinolone compounds suitable for use as adjuvants in the invention include Imiquimod and its homologues (e.g "Resiquimod 3M"), described further in refs. 142 and 143.

N. Thiosemicarbazone Compounds.

Examples of thiosemicarbazone compounds, as well as methods of formulating, manufacturing, and screening for compounds all suitable for use as adjuvants in the invention include those described in ref. 144. The thiosemicarbazones are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF- α .

O. Tryptanthrin compounds.

Examples of tryptanthrin compounds, as well as methods of formulating, manufacturing, and screening for compounds all suitable for use as adjuvants in the invention include those described in ref. 145. The tryptanthrin compounds are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF- α .

The invention may also comprise combinations of aspects of one or more of the adjuvants identified above. For example, the following adjuvant compositions may be used in the invention: (1) a saponin and an oil-in- water emulsion [146]; (2) a saponin (e.g QS21) + a non-toxic LPS derivative (e.g. 3dMPL) [147]; (3) a saponin (e.g. QS21) + a non-toxic LPS derivative (e.g 3dMPL) + a cholesterol; (4) a saponin (e.g QS21) + 3dMPL + IL-12 (optionally + a sterol) [148]; (5) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions [149]; (6) SAF, containing 10% squalane, 0.4% Tween 80TM, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion. (7) RibiTM adjuvant system (RAS), (Ribi Immunochem) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DetoxTM); (8) one or more mineral salts (such as an aluminum salt) + a non-toxic derivative of LPS (such as 3dMPL); and (9) one or more mineral salts (such as an aluminum salt) + an immunostimulatory oligonucleotide (such as a nucleotide sequence including a CpG motif).

Other substances that act as immunostimulating agents are disclosed in chapter 7 of ref. 81.

The use of an aluminium hydroxide or aluminium phosphate adjuvant is preferred, and conjugates are generally adsorbed to these salts [e.g examples 7 & 8 of ref. 9; example J of ref. 10]. Mixing with aluminium salts with no adsorption is also possible [27, 76]. Calcium phosphate is another preferred adjuvant. Conjugates may be mixed with (and optionally adsorbed to) the adjuvants separately and then the conjugates may be mixed together, or the conjugates may be mixed together and then mixed with adjuvant.

The pH of compositions used according to the invention is preferably between 6 and 8, preferably about 7. Stable pH may be maintained by the use of a buffer. Where a composition comprises an aluminium hydroxide salt, it is preferred to use a histidine buffer [150]. The composition may be sterile and/or pyrogen-free. Compositions may be isotonic with respect to humans.

Compositions may include a preservative (e.g thiomersal, 2-phenoxyethanol) , or may be preservative-free. Preferred compositions of the invention do not include any mercurial material e.g. they are thiomersal-free.

To prevent interference between antigens, particularly conjugate antigens, it is possible to include a polyanionic polymer, such as poly-L-glutamic acid [151].

Compositions may be presented in vials, or they may be presented in ready- filled syringes. The syringes may be supplied with or without needles. A syringe will include a single dose of the composition, whereas a vial may include a single dose or multiple doses. Injectable compositions will usually be liquid solutions or

suspensions. Alternatively, they may be presented in solid form (e.g freeze-dried) for solution or suspension in liquid vehicles prior to injection.

5 Compositions may be packaged in unit dose form or in multiple dose form. For multiple dose forms, vials are preferred to pre-filled syringes. Effective dosage volumes can be routinely established, but a typical human dose of the composition for injection has a volume of 0.5ml.

10 Where a composition is to be prepared extemporaneously prior to use (e.g where a component is presented in lyophilised form) and is presented as a kit, the kit may comprise two vials, or it may comprise one ready-filled syringe and one vial, with the contents of the syringe being used to reactivate the contents of the vial prior to injection. For compositions that include a serogroup A capsular saccharide then the serogroup A saccharide may be lyophilised, whereas saccharide(s) from other serogroup(s) may be present in liquid form.

15 Compositions will comprise an immunologically effective amount of the meningococcal conjugates, as well as any other components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, elicits a protective anti-meningococcal or anti-pneumococcal immune response in patients. This amount varies depending upon the health and physical condition of the individual to be
20 treated, age, the taxonomic group of individual to be treated (e.g non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined
25 through routine trials, and a typical quantity of each meningococcal antigen per dose is between 1 µg and 20 µg per serogroup/serotype (measured in terms of saccharide) e.g between 2 and 10 µg per serogroup/serotype. A dose of about 4 µg per serogroup/serotype may be used (i.e. a total of 16 µg in a tetravalent MenACWY mixture).

30 The total amount of carrier protein in a composition preferably does not exceed 100 µg /dose e.g it is ≤90 µg /dose, ≤80 µg /dose, ≤70 µg /dose, ≤60 µg /dose, ≤50 µg /dose, etc. The total amount of carrier protein in a composition will generally be at least 10 µg /dose.

35 General The term "comprising" encompasses "including" as well as "consisting" e.g a composition "comprising" X may consist exclusively of X or may include something additional eg X + Y. The term "about" in relation to a numerical value x means, for example, x±10%.

40 The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

45 The term "saccharide" throughout this specification may indicate polysaccharide or oligosaccharide and includes both. Polysaccharides are isolated from bacteria or isolated from bacteria and sized to some degree by known methods (see for example EP497524 and EP497525) and preferably by microfluidisation. Polysaccharides can be sized in order to reduce viscosity in polysaccharide samples and/or to improve filterability for conjugated products. Oligosaccharides have a low number of repeat units (typically 5-30 repeat units) and are typically hydrolysed polysaccharides.

MODES FOR CARRYING OUT THE INVENTION

Study No.: 217744/085 (DTPa-Hep B-IPV-085)

Title: A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepB-IPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER.

Rationale: The present primary vaccination study evaluated the safety and immunogenicity of GSK Biologicals' DTaP-HepB-IPV combined vaccine (DTaP-HBV-IPV) when co-administered with *Haemophilus influenzae* type b Conjugate Vaccine (Hib) and Pneumococcal 7-valent Conjugate Vaccine (PnC) compared to separate administration of DTaP vaccine (DTaP), Hepatitis B Recombinant vaccine (HBV), Poliovirus Vaccine Inactivated (IPV), Hib and PnC and to DTaP-HBV-IPV when coadministered with Hib with PnC administered two weeks after each of the DTaP-HBV-IPV doses.

Phase: III

Study Period: February 8, 2002 to August 4, 2003.

Study Design: Open, multicenter, primary vaccination study with three parallel groups. Healthy infants at 2 months of age were randomized to one of the three groups with a balanced allocation (1:1:1).

Centres: 12 centers in the United States.

Indication: DTaP, HBV, IPV, Hib and PnC vaccines are indicated for active immunization of infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, *Haemophilus influenzae* type b, and *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F diseases.

Treatment: Study groups were as follow:

- Combination Vaccine Group: receiving one dose each of DTaP-HBV-IPV + Hib + PnC at 2, 4, 6 months of age.
- Separate Vaccine Group: receiving one dose each of DTaP + HBV + IPV + Hib + PnC at 2, 4, 6 months of age; HBV was not to be administered at 4 months of age to subjects who received a dose of hepatitis B vaccine prior to enrollment in this study.
- Staggered Vaccine Group: receiving one dose each of DTaP-HBV-IPV + Hib at 2, 4, 6 months of age (PnC administered 2 weeks following each dose of DTaP-HBV-IPV + Hib).

All vaccines were to be administered by deep intramuscular injection except for IPV, which was administered by subcutaneous injection in the left deltoid. DTaP-HBV-IPV or DTaP injections were to be administered in the upper right anterolateral thigh, and HBV injections were to be administered in the lower right anterolateral thigh. PnC and Hib injections were to be administered in the upper and lower left anterolateral thigh, respectively.

Objectives: The primary objective was to demonstrate that the immunogenicity of GSK Biologicals' DTaP-HBV-IPV combined vaccine co-administered with Hib and PnC as a three dose primary vaccination course is non-inferior to that of separately administered DTaP, HBV, IPV, Hib and PnC with respect to diphtheria, tetanus, pertussis, and poliovirus.

Primary Outcome/Efficacy Variable (s):

Criteria for meeting this objective (one month after the third dose):

- upper limit of two-sided 90% CI on geometric mean concentration (GMC) ratio (Separate Vaccine Group over Combination Vaccine Group) below 1.5 for each pertussis antigen
- upper limit of two-sided 95% CI on absolute difference (Separate Vaccine Group minus Combination Vaccine Group) for seroprotection rate below 10% for D and T antigens:
 - seroprotection status for anti-D and anti-T antibody concentrations ≥ 0.1 IU/ml
- upper limit of two-sided 95% CI on absolute difference (Separate Vaccine Group minus Combination Vaccine Group) for seroprotection rate below 5% for the three Polio antigens:
 - seroprotection status for anti-poliovirus type 1, 2 and 3 antibody titers $\geq 1:8$

Secondary Outcome/Efficacy Variable (s):

- Immunogenicity one month after the third dose of the primary series of vaccinations:
 - Vaccine response to PT, FHA and PRN, defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations <cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations $\geq$ cut-off value)

- Seropositivity status for anti-PT, anti-FHA, anti-PRN (defined as antibody concentrations ≥ 5 EL.U/ml).
- Seroprotection to hepatitis B (defined as anti-HBs antibody concentrations ≥ 10 mIU/ml).
- Seroprotection status for anti-PRP (defined as antibody concentrations ≥ 0.15 μ g/ml and ≥ 1.0 μ g/ml).
- Seropositivity status for anti-pneumococcal antibody concentrations to the 7 PnC serotypes (defined as antibody concentrations ≥ 0.05 μ g/ml).
- Anti-diphtheria, anti-tetanus, anti-HBs and anti-PRP antibody concentrations, and anti-poliovirus types 1, 2 and 3 antibody titers
- Safety:
 - Incidence of fever of any intensity (rectal temperature $\geq 38.0^{\circ}\text{C}$ / $\geq 100.4^{\circ}\text{F}$) occurring within 4 days (days 0 - day 3) after each vaccine dose
 - Incidence of grade 2 or grade 3 fever ($>38.5^{\circ}\text{C}$ / $>101.3^{\circ}\text{F}$) occurring within four days after each vaccine dose
 - Incidence of grade 3 fever ($>39.5^{\circ}\text{C}$ / $>103.1^{\circ}\text{F}$) occurring within four days after each vaccine dose
 - Incidence of fever $>39.0^{\circ}\text{C}$ ($>102.2^{\circ}\text{F}$) occurring within four days after each vaccine dose
 - Incidence of other solicited general symptoms (any intensity, grade 2 or grade 3 and grade 3) occurring within four days after each vaccine dose
 - Incidence of solicited local symptoms (any intensity, grade 2 or grade 3 and grade 3) occurring within four days after each vaccine dose
 - Incidence of antipyretic use within four days after each vaccine dose
 - Incidence of antibiotic use within four days after each vaccine dose
 - Incidence of unsolicited adverse events (AEs) occurring throughout the entire active phase of the study (including the 31-day follow-up period after the last dose of DTaP/DTaP-HBV-IPV)
 - Occurrence of SAEs throughout the entire study including the six month (182 day) follow-up period after the last dose of DTaP/DTaP-HBV-IPV.
- Extended safety follow-up period up to six months after the last dose of study vaccine (five months after end of active phase)

Statistical methods:

The analyses were performed on the Total vaccinated cohort, the According-To-Protocol (ATP) cohort and the Extended Safety Follow-up (ESFU) cohort.

- The Total vaccinated cohort includes all subjects having received at least one vaccine dose and for whom data for endpoint measures were available. In the Total vaccinated cohort, subjects were analyzed according to the vaccine(s) that were actually administered.
- The ATP cohort for immunogenicity includes subjects for whom assay results were available for antibodies against at least one study vaccine antigen one month after the 3-dose primary vaccination.
- The ESFU cohort includes all subjects for whom follow-up data were available beyond the 31-day period (Day 0 – Day 30) following the last dose of vaccine (from Day 31 post last dose to the last study contact), and includes those subjects who dropped out before the scheduled 5-month follow-up contact at study completion (six months post last dose of study vaccine).

Analysis of Immunogenicity:

The immunogenicity analyses were based on the ATP cohort.

GMCs/GMTs and seropositivity/seroprotection rates were calculated with their 95% CI for each group, at each blood sampling time point.

Standardized asymptotic 95% Confidence Intervals (CIs) for the difference in pertussis vaccine response rates and in seroprotection rates of D, T, poliovirus types 1, 2 and 3 (Separate Vaccine Group minus Combination Vaccine Group) one month after the third dose were computed. For each pertussis antigen one month after the third vaccine dose, the 90% CIs of the GMC/GMT ratios (Separate Vaccine Group divided by Combination Vaccine Group) were computed using an ANCOVA model on the logarithm10 transformation of the concentrations/titers. The ANCOVA model included the vaccine group as fixed effect (all three groups) and the pre-vaccination concentration/titer as regressor.

The primary objective was reached if the upper limits of the 90% CIs for the GMC/GMT ratios and of the asymptotic 95% CIs for the differences in seroprotection rates for all primary endpoints were all below the clinical limits defining non-inferiority

Analysis of Safety:

For solicited symptoms, the analyses were performed on the total vaccinated cohort. For each solicited

symptom, the percentage of subjects with the symptom and its exact 95% Confidence Interval (CI) was summarized by vaccine group, by dose and across doses.

The percentage of subjects using antibiotics and antipyretics within the four days post-vaccination was summarized with their 95 % CI.

The percentage of subjects reporting unsolicited symptoms during the active phase (from dose 1 to day 30 following last vaccine dose) was summarized by vaccine group according to the WHO preferred term and reported to the total vaccinated cohort.

The percentage of subjects reporting unsolicited symptoms during the Extended Safety Follow-up Period (occurring from day 31 after last vaccine dose to last study contact) was summarized by vaccine group according to the WHO preferred term and reported to the ESFU cohort.

SAEs reported during the entire study including the Extended Safety Follow-up Period (ESFU) were also described and reported to the total vaccinated cohort.

Study Population: Healthy male or female infants born after a normal gestation period of 36-42 weeks, 6 - 12 weeks of age at the time of the first primary vaccination, and free of obvious health problems as established by medical history and clinical examination before entering into the study. The subjects were not to have been previously vaccinated against diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b, and/or *Streptococcus pneumoniae* disease; more than one previous dose of hepatitis B vaccine at least 30 days prior to enrollment, or have had a history of these diseases. Subjects' parents/guardians provided written informed consent.

Number of Subjects (Modified ITT Cohort)	Separate Vaccine Group	Staggered Vaccine Group	Combination Vaccine Group
Planned, N	190	190	190
Randomized, N	188	188	199
Completed, n (%)	172 (91.5)	177 (94.1)	183 (92.0)
Total Number Subjects Withdrawn, N (%)	16 (8.5)	11 (5.9)	16 (8.0)
Withdrawn due to Adverse Events, n (%)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable	Not applicable	Not applicable
Withdrawn for other reasons, n (%)	16 (8.5)	11 (5.9)	16 (8.0)
Demographics			
Group			
Total Vaccinated Cohort, N	188	188	199
Females: Males	95:93	97:91	104:95
Mean age, weeks (SD)	8.6 (1.24)	8.8 (1.41)	8.6 (1.22)
Race: White, n (%)	157 (83.5)	160 (85.1)	167 (83.9)

Primary Efficacy Results:

Differences in response rates between the Separate Vaccine Group and Combination Vaccine Group with their 95% CIs one month following the third DTaP/DTaP-HB-IPV vaccination for anti-diphtheria, anti-tetanus and the three Polio antigens – ATP cohort

Endpoint	Separate Vaccine Group			Combination Vaccine Group			Separate minus Combination Vaccine Group		
	N	n	Rate (%)	N	n	Rate (%)	Diff in rates (%)	95% CI	
								LL	UL
anti-D ≥ 0.1 IU/ml	155	153	98.7	168	167	99.4	-0.70	-4.05	2.12*
anti-T ≥ 0.1 IU/ml	155	152	98.1	168	168	100.0	-1.94	-5.54	0.32*
anti-poliovirus 1 $\geq 1:8$	153	153	100.0	168	168	100.0	0.00	-2.45	2.24**
anti-poliovirus 2 $\geq 1:8$	153	153	100.0	168	168	100.0	0.00	-2.45	2.24**
anti-poliovirus 3 $\geq 1:8$	153	153	100.0	168	168	100.0	0.00	-2.45	2.24**

N = number of subjects with available results

n = number of subjects with concentration/titer above the specified cut-off or with a vaccine response

% = $n/N \times 100$

95% CI = 95% standardized asymptotic confidence interval; LL = lower limit; UL = upper limit
 *non-inferiority criterion met: upper limit below the 10 % difference clinical limit for non-inferiority
 ** non-inferiority criterion met: upper limit below the 5 % difference clinical limit for non-inferiority

Primary Efficacy Results:

Ratios of adjusted GMCs/GMTs between Separate Vaccine Group and Combination Vaccine Group with their 90% CIs one month following the third vaccination for each Pertussis antigen – ATP cohort

Endpoint	Separate Vaccine Group		Combination Vaccine Group		Separate/Combination Vaccine Group		
	N	Adjusted GMC/GMT	N	Adjusted GMC/GMT	Ratio of adjusted GMC/GMT	90% CI	
						LL	UL
anti-PT concentration	142	28.6	155	48.1	0.59	0.51	0.70*
anti-FHA concentration	141	97.6	154	111.9	0.87	0.76	1.00*
anti-PRN concentration	142	80.6	156	95.3	0.85	0.72	0.99*

N: number of subjects with both pre- and post-vaccination results available

90% CI = 90% confidence interval; LL = Lower Limit; UL = Upper Limit (Ancova model including all 3 vaccine groups: adjustment for baseline antibody concentrations/titers)

* non-inferiority criterion met: upper limit below the 1.5 fold clinical limit for non-inferiority

Secondary Outcome Variable (s):

Vaccine response rates for anti-PT, anti-FHA and anti-PRN antibodies one month following the third DTaP/DTaP-HBV-IPV vaccination by pre-vaccination seropositivity status – ATP cohort

Antibody	Group	Pre-vaccination seropositivity status	N	Responders			
				n	%	95% CI	
						LL	UL
anti-PT	Separate	Seropositive	14	10	71.4	41.9	91.6
		Seronegative	128	125	97.7	93.3	99.5
		Total	142	135	95.1	90.1	98.0
	Staggered	Seropositive	16	14	87.5	61.7	98.4
		Seronegative	136	134	98.5	94.8	99.8
		Total	152	148	97.4	93.4	99.3
	Combination	Seropositive	18	18	100	81.5	100
		Seronegative	137	135	98.5	94.8	99.8
		Total	155	153	98.7	95.4	99.8
anti-FHA	Separate	Seropositive	86	81	94.2	87.0	98.1
		Seronegative	55	55	100	93.5	100
		Total	141	136	96.5	91.9	98.8
	Staggered	Seropositive	92	89	96.7	90.8	99.3
		Seronegative	61	61	100	94.1	100
		Total	153	150	98.0	94.4	99.6
	Combination	Seropositive	95	93	97.9	92.6	99.7
		Seronegative	59	59	100	93.9	100
		Total	154	152	98.7	95.4	99.8
anti-PRN	Separate	Seropositive	66	59	89.4	79.4	95.6
		Seronegative	76	76	100	95.3	100
		Total	142	135	95.1	90.1	98.0
	Staggered	Seropositive	71	62	87.3	77.3	94.0
		Seronegative	83	83	100	95.7	100
		Total	154	145	94.2	89.2	97.3
	Combination	Seropositive	85	72	84.7	75.3	91.6
		Seronegative	71	71	100	94.9	100
		Total	156	143	91.7	86.2	95.5

N = number of subjects with both pre- and post-vaccination results available

n = number of responders

% = $n/N \times 100$

95% CI = exact 95% confidence interval; LL = lower limit, UL = upper limit

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response to PT, FHA and PRN is defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations < cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations < cut-off value).

Secondary Outcome Variable (s):

Seropositivity rates and GMCs for anti-PT, anti-FHA and anti-PRN antibody concentrations prior to vaccination and one month following the third DTaP/DTaP-HBV-IPV vaccination – ATP cohort

Antibody	Group	Timing	N	≥ 5 EL.U/ml				GMC		
				n	%	95% CI		Value	95% CI	
						LL	UL		LL	UL
anti-PT	Separate	PRE	143	15	10.5	6.0	16.7	2.9	2.7	3.1
		PIII	155	151	97.4	93.5	99.3	28.9	25.2	33.2
	Staggered	PRE	155	17	11.0	6.5	17.0	2.9	2.7	3.2
		PIII	158	155	98.1	94.6	99.6	50.3	44.6	56.7
	Combination	PRE	156	18	11.5	7.0	17.6	2.8	2.7	3.0
		PIII	168	166	98.8	95.8	99.9	48.7	42.8	55.4
anti-FHA	Separate	PRE	142	87	61.3	52.7	69.3	6.5	5.6	7.6
		PIII	155	154	99.4	96.5	100.0	96.4	85.5	108.7
	Staggered	PRE	156	94	60.3	52.1	68.0	6.7	5.7	7.9
		PIII	158	158	100.0	97.7	100.0	117.7	105.9	130.9
	Combination	PRE	155	95	61.3	53.1	69.0	6.8	5.8	8.0
		PIII	168	168	100.0	97.8	100.0	113.7	101.5	127.3
anti-PRN	Separate	PRE	143	67	46.9	38.5	55.4	5.3	4.5	6.2
		PIII	155	153	98.7	95.4	99.8	79.1	66.8	93.6
	Staggered	PRE	157	72	45.9	37.9	54.0	5.5	4.7	6.4
		PIII	158	158	100.0	97.7	100.0	99.5	87.5	113.2
	Combination	PRE	157	85	54.1	46.0	62.1	6.4	5.4	7.5
		PIII	168	168	100.0	97.8	100.0	93.7	82.3	106.7

N = number of subjects with available results

n = number of subjects with concentration above the specified cut-off

% = $n/N \times 100$

95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit

PRE = immediately before the first vaccination

PIII = approximately one month following the third DTaP/DTaP-HBV-IPV vaccination (approximately 7 months of age)

Secondary Outcome Variable (s):

Seroprotection rates and GMCs for anti-HBs antibody prior to vaccination and one month following the third DTaP/DTaP-HBV-IPV vaccination – ATP cohort

Antibody	Group	Timing	N	≥ 10 mIU/ml				GMC		
				n	%	95% CI		Value	95% CI	
						LL	UL		LL	UL
Total subjects regardless of hepatitis B vaccination status prior to study entry										
anti-HBs	Separate	PRE	141	16	11.3	6.6	17.8	6.7	5.7	7.9
		PIII	154	152	98.7	95.4	99.8	667.5	534.1	834.3
	Staggered	PRE	151	26	17.2	11.6	24.2	8.8	7.1	11.0
		PIII	158	158	100.0	97.7	100.0	1515.3	1250.6	1835.9
	Combination	PRE	150	34	22.7	16.2	30.2	10.1	7.9	13.0
		PIII	167	164	98.2	94.8	99.6	1123.6	912.0	1384.2

N = number of subjects with available results

n = number of subjects with concentration above the specified cut-off
 % = $n/N \times 100$
 95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit
 PRE = immediately before the first vaccination
 PIII = approximately one month following the third DTaP/DTaP-HBV-IPV vaccination (approximately 7 months of age)

Secondary Outcome Variable (s):

Seroprotection rates and GMCs for anti-PRP antibody concentrations prior to vaccination and one month following the third DTaP/DTaP-HBV-IPV vaccination – ATP cohort

Group	Timing	N	$\geq 0.15 \mu\text{g/ml}$				$\geq 1 \mu\text{g/ml}$				GMC		
			n	%	95% CI		n	%	95% CI		Value	95% CI	
					LL	UL			LL	UL		LL	UL
Separate	PRE	143	101	70.6	62.4	77.9	13	9.1	4.9	15.0	0.247	0.209	0.293
	PIII	155	154	99.4	96.5	100.0	141	91.0	85.3	95.0	9.246	7.378	11.587
Staggered	PRE	156	103	66.0	58.0	73.4	15	9.6	5.5	15.4	0.215	0.184	0.252
	PIII	158	158	100.0	97.7	100.0	150	94.9	90.3	97.8	8.384	7.020	10.013
Combination	PRE	157	107	68.2	60.3	75.4	14	8.9	5.0	14.5	0.224	0.193	0.261
	PIII	168	168	100.0	97.8	100.0	161	95.8	91.6	98.3	9.619	7.995	11.572

N = number of subjects with available results

n = number of subjects with concentration above the specified cut-off

% = $n/N \times 100$

95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit

PRE = immediately before the first vaccination

PIII = approximately one month following the third DTaP/DTaP-HBV-IPV vaccination (approximately 7 months of age)

Secondary Outcome Variable (s):

Seropositivity rates and GMCs for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F anti-S. pneumoniae antibodies prior to vaccination and following the third PnC vaccination – ATP cohort

anti-S. pneumoniae serotype	Group	Timing	N	$\geq 0.05 \mu\text{g/ml}$				GMC		
				n	%	95% CI		Value	95% CI	
						LL	UL		LL	UL
4	Separate	PRE	128	38	29.7	21.9	38.4	0.04	0.04	0.05
		PIII	156	156	100.0	97.7	100.0	2.07	1.81	2.37
	Staggered	PRE	141	39	27.7	20.5	35.8	0.04	0.04	0.05
		PIIIP	155	155	100.0	97.6	100.0	1.62	1.44	1.83
	Combination	PRE	144	47	32.6	25.1	40.9	0.04	0.04	0.05
		PIII	164	163	99.4	96.6	100.0	1.74	1.54	1.98
6B	Separate	PRE	132	69	52.3	43.4	61.0	0.07	0.06	0.09
		PIII	148	134	90.5	84.6	94.7	0.67	0.52	0.87
	Staggered	PRE	142	75	52.8	44.3	61.2	0.08	0.06	0.09
		PIIIP	154	148	96.1	91.7	98.6	0.59	0.49	0.72
	Combination	PRE	146	82	56.2	47.7	64.4	0.10	0.08	0.13
		PIII	163	156	95.7	91.4	98.3	0.80	0.65	0.99
9V	Separate	PRE	126	63	50.0	41.0	59.0	0.07	0.06	0.09
		PIII	151	151	100.0	97.6	100.0	1.60	1.39	1.85
	Staggered	PRE	135	81	60.0	51.2	68.3	0.08	0.07	0.10
		PIIIP	150	150	100.0	97.6	100.0	1.11	0.97	1.28
	Combination	PRE	138	77	55.8	47.1	64.2	0.08	0.06	0.10
		PIII	163	163	100.0	97.8	100.0	1.55	1.36	1.77

14	Separate	PRE	130	121	93.1	87.3	96.8	0.46	0.35	0.61
		PIII	156	156	100.0	97.7	100.0	6.32	5.39	7.41
	Staggered	PRE	141	129	91.5	85.6	95.5	0.38	0.30	0.48
		PIIIP	154	154	100.0	97.6	100.0	4.51	3.91	5.19
	Combination	PRE	146	137	93.8	88.6	97.1	0.60	0.46	0.77
		PIII	166	166	100.0	97.8	100.0	4.68	4.04	5.43
18C	Separate	PRE	129	75	58.1	49.1	66.8	0.09	0.07	0.12
		PIII	153	153	100.0	97.6	100.0	2.96	2.53	3.47
	Staggered	PRE	139	85	61.2	52.5	69.3	0.09	0.07	0.11
		PIIIP	156	156	100.0	97.7	100.0	2.37	2.06	2.72
	Combination	PRE	143	90	62.9	54.5	70.9	0.11	0.09	0.14
		PIII	167	166	99.4	96.7	100.0	2.63	2.31	3.00
19F	Separate	PRE	131	101	77.1	68.9	84.0	0.18	0.14	0.23
		PIII	147	147	100.0	97.5	100.0	1.05	0.91	1.22
	Staggered	PRE	140	112	80.0	72.4	86.3	0.19	0.15	0.24
		PIIIP	149	149	100.0	97.6	100.0	0.75	0.66	0.86
	Combination	PRE	143	118	82.5	75.3	88.4	0.27	0.21	0.34
		PIII	161	160	99.4	96.6	100.0	1.09	0.95	1.25
23F	Separate	PRE	128	66	51.6	42.6	60.5	0.07	0.06	0.09
		PIII	146	141	96.6	92.2	98.9	1.81	1.45	2.25
	Staggered	PRE	137	81	59.1	50.4	67.4	0.09	0.07	0.11
		PIIIP	153	150	98.0	94.4	99.6	1.29	1.09	1.53
	Combination	PRE	140	79	56.4	47.8	64.8	0.11	0.08	0.14
		PIII	162	158	97.5	93.8	99.3	1.48	1.23	1.79

N = number of subjects with available results

n = number of subjects with concentration above the specified cut-off

% = $n/N \times 100$

95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit

PRE = immediately before the first vaccination

PIII = approximately one month following the third PnC vaccination for subjects in the Combination Vaccine Group and Separate Vaccine Group (approximately 7 months of age)

PIIIP = approximately two weeks following the third PnC vaccination for subjects in the Staggered Vaccine Group (approximately 7 months of age)

Secondary Outcome Variable (s):

Seroprotection rates and GMCs for anti-diphtheria and anti-tetanus antibody concentrations prior to vaccination and one month following the third DTaP/DTaP-HBV-IPV vaccination – ATP cohort

Antibody	Group	Timing	N	≥ 0.1 IU/ml				GMC		
				n	%	95% CI		Value	95% CI	
						LL	UL		LL	UL
anti-D	Separate	PRE	143	75	52.4	43.9	60.9	0.117	0.100	0.137
		PIII	155	153	98.7	95.4	99.8	1.564	1.354	1.806
	Staggered	PRE	157	76	48.4	40.4	56.5	0.111	0.095	0.128
		PIII	157	157	100.0	97.7	100.0	3.238	2.889	3.630
	Combination	PRE	157	64	40.8	33.0	48.9	0.096	0.083	0.111
		PIII	168	167	99.4	96.7	100.0	1.987	1.761	2.242
anti-T	Separate	PRE	143	134	93.7	88.4	97.1	0.583	0.489	0.696
		PIII	155	152	98.1	94.4	99.6	1.346	1.166	1.554
	Staggered	PRE	157	142	90.4	84.7	94.6	0.561	0.468	0.672
		PIII	158	158	100.0	97.7	100.0	2.240	2.017	2.487
	Combination	PRE	157	143	91.1	85.5	95.0	0.527	0.443	0.628
		PIII	168	168	100.0	97.8	100.0	2.428	2.180	2.704

N = number of subjects with available results

n = number of subjects with concentration above the specified cut-off

% = $n/N \times 100$

95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit

PRE = immediately before the first vaccination

PIII = approximately one month following the third DTaP/DTaP-HBV-IPV vaccination (approximately 7 months of age)

Secondary Outcome Variable (s):

Seroprotection rates and GMTs for anti-poliovirus type 1, anti-poliovirus type 2 and anti-poliovirus type 3 antibody titers prior to vaccination and one month following the third DTaP/DTaP-HBV-IPV vaccination – Total vaccinated cohort

Antibody	Group	Timing	N	≥ 1:8				GMT		
				n	%	95% CI		Value	95% CI	
						LL	UL		LL	UL
anti-poliovirus 1	Separate	PRE	143	115	80.4	73.0	86.6	22.0	17.8	27.2
		PIII	153	153	100.0	97.6	100.0	225.0	191.3	264.7
	Staggered	PRE	152	120	78.9	71.6	85.1	20.7	16.9	25.3
		PIII	156	156	100.0	97.7	100.0	793.1	660.3	952.7
	Combination	PRE	153	121	79.1	71.8	85.2	20.7	16.7	25.5
		PIII	168	168	100.0	97.8	100.0	678.0	568.1	809.2
anti-poliovirus 2	Separate	PRE	143	100	69.9	61.7	77.3	13.8	11.5	16.6
		PIII	153	153	100.0	97.6	100.0	228.1	198.1	262.7
	Staggered	PRE	152	106	69.7	61.8	76.9	13.5	11.3	16.0
		PIII	156	156	100.0	97.7	100.0	608.8	500.8	740.2
	Combination	PRE	153	124	81.0	73.9	86.9	15.0	12.7	17.8
		PIII	168	168	100.0	97.8	100.0	578.3	479.3	697.8
anti-poliovirus 3	Separate	PRE	143	39	27.3	20.2	35.3	6.0	5.2	6.9
		PIII	153	153	100.0	97.6	100.0	454.2	390.6	528.2
	Staggered	PRE	152	37	24.3	17.8	32.0	5.8	5.2	6.6
		PIII	156	156	100.0	97.7	100.0	1167.5	973.9	1399.6
	Combination	PRE	153	49	32.0	24.7	40.0	6.8	5.8	8.1
		PIII	168	168	100.0	97.8	100.0	1269.2	1061.3	1517.8

N = number of subjects with available results

n = number of subjects with titer above the specified cut-off

% = $n/N \times 100$

95% CI = 95% confidence interval; LL = Lower Limit; UL = Upper Limit

PRE = immediately before the first vaccination

PIII = approximately one month following the third DTaP/DTaP-HBV-IPV vaccination (approximately 7 months of age)

Secondary Outcome Variable (s):

Incidence of fever, excluding doses with no temperature recording or tympanic measurements, by intensity and causal relationship reported within four days following DTaP/DTaP-HBV-IPV vaccination (Day 0 – Day 3), by dose and across doses – Total vaccinated cohort

	Rectal temperature*	Separate Vaccine Group				Staggered Vaccine Group				Combination Vaccine Group			
		n	%	95% CI		n	%	95% CI		n	%	95% CI	
				LL	UL			LL	UL			LL	UL
Dose 1		N = 187				N = 185				N = 197			

	≥ 38.0°C	40	21.4	15.7	28.0	35	18.9	13.5	25.3	63	32.0	25.5	39.0
	> 38.5°C	9	4.8	2.2	8.9	3	1.6	0.3	4.7	12	6.1	3.2	10.4
	> 39°C	2	1.1	0.1	3.8	2	1.1	0.1	3.9	4	2.0	0.6	5.1
	> 39.5°C	0	0.0	0.0	2.0	0	0.0	0.0	2.0	1	0.5	0.0	2.8
	Causally related	33	17.6	12.5	23.9	33	17.8	12.6	24.1	62	31.5	25.1	38.5
Dose 2		N = 180				N = 181				N = 192			
	≥ 38.0°C	59	32.8	26.0	40.2	49	27.1	20.7	34.2	82	42.7	35.6	50.0
	> 38.5°C	13	7.2	3.9	12.0	10	5.5	2.7	9.9	21	10.9	6.9	16.2
	> 39°C	1	0.6	0.0	3.1	7	3.9	1.6	7.8	9	4.7	2.2	8.7
	> 39.5°C	0	0.0	0.0	2.0	0	0.0	0.0	2.0	2	1.0	0.1	3.7
	Causally related	55	30.6	23.9	37.8	46	25.4	19.2	32.4	77	40.1	33.1	47.4
Dose 3		N = 176				N = 180				N = 190			
	≥ 38.0°C	53	30.1	23.4	37.5	41	22.8	16.9	29.6	68	35.8	29.0	43.0
	> 38.5°C	12	6.8	3.6	11.6	9	5.0	2.3	9.3	21	11.1	7.0	16.4
	> 39°C	6	3.4	1.3	7.3	3	1.7	0.3	4.8	8	4.2	1.8	8.1
	> 39.5°C	1	0.6	0.0	3.1	1	0.6	0.0	3.1	2	1.1	0.1	3.8
	Causally related	47	26.7	20.3	33.9	35	19.4	13.9	26.0	63	33.2	26.5	40.3
Across doses		N = 188				N = 187**				N = 197**			
	≥ 38.0°C	101	53.7	46.3	61.0	87	46.5	39.2	53.9	134	68.0	61.0	74.5
	> 38.5°C	30	16.0	11.0	22.0	21	11.2	7.1	16.7	45	22.8	17.2	29.3
	> 39°C	9	4.8	2.2	8.9	12	6.4	3.4	10.9	20	10.2	6.3	15.2
	> 39.5°C	1	0.5	0.0	2.9	1	0.5	0.0	2.9	5	2.5	0.8	5.8
	Causally related	94	50.0	42.6	57.4	82	43.9	36.6	51.3	130	66.0	58.9	72.6
N = number of subjects with a symptom sheet completed n/% = number/percentage of subjects reporting the specified symptom 95% CI = 95% confidence interval (exact method for proportion); LL = lower limit, UL = upper limit *Fever (rectal route): temperature ≥ 38.0° C (≥100.4°F). Axillary recordings were increased by 1°C to derive equivalent rectal temperatures and are included. **post vaccination information not available for one subject in staggered vaccine group and two subjects in combination vaccine group													

Secondary Outcome Variable (s):

Incidence of solicited general symptoms, excluding fever, reported within four days following DTaP/DTaP-HBV-IPV vaccination (Day 0 – Day 3), by dose– Total vaccinated cohort

	Intensity	Separate Vaccine Group				Staggered Vaccine Group				Combination Vaccine Group			
		n	%	95% CI		n	%	95% CI		n	%	95% CI	
				LL	UL			LL	UL			LL	UL
Dose 1		N=187				N=187				N=198			
Drowsiness													
	Any	110	58.8	51.4	66.0	107	57.2	49.8	64.4	123	62.1	55.0	68.9
	Grade 2 or 3	34	18.2	12.9	24.5	28	15.0	10.2	20.9	37	18.7	13.5	24.8
	Grade 3	4	2.1	0.6	5.4	5	2.7	0.9	6.1	4	2.0	0.6	5.1
	Causally related	107	57.2	49.8	64.4	103	55.1	47.7	62.3	120	60.6	53.4	67.5
Irritability													
	Any	116	62.0	54.7	69.0	119	63.6	56.3	70.5	134	67.7	60.7	74.1
	Grade 2 or 3	39	20.9	15.3	27.4	35	18.7	13.4	25.1	46	23.2	17.5	29.7

	Grade 3	2	1.1	0.1	3.8	6	3.2	1.2	6.9	10	5.1	2.4	9.1
	Causally related	113	60.4	53.0	67.5	114	61.0	53.6	68.0	132	66.7	59.6	73.2
Loss of appetite													
	Any	56	29.9	23.5	37.1	56	29.9	23.5	37.1	64	32.3	25.9	39.3
	Grade 2 or 3	9	4.8	2.2	8.9	12	6.4	3.4	10.9	13	6.6	3.5	11.0
	Grade 3	1	0.5	0.0	2.9	1	0.5	0.0	2.9	0	0.0	0.0	1.8
	Causally related	56	29.9	23.5	37.1	55	29.4	23.0	36.5	61	30.8	24.5	37.7
Dose 2		N=180				N=183				N=192			
Drowsiness													
	Any	104	57.8	50.2	65.1	71	38.8	31.7	46.3	103	53.6	46.3	60.9
	Grade 2 or 3	25	13.9	9.2	19.8	17	9.3	5.5	14.5	28	14.6	9.9	20.4
	Grade 3	3	1.7	0.3	4.8	0	0.0	0.0	2.0	5	2.6	0.9	6.0
	Causally related	99	55.0	47.4	62.4	68	37.2	30.1	44.6	96	50.0	42.7	57.3
Irritability													
	Any	113	62.8	55.3	69.9	103	56.3	48.8	63.6	148	77.1	70.5	82.8
	Grade 2 or 3	41	22.8	16.9	29.6	34	18.6	13.2	25.0	68	35.4	28.7	42.6
	Grade 3	8	4.4	1.9	8.6	4	2.2	0.6	5.5	9	4.7	2.2	8.7
	Causally related	110	61.1	53.6	68.3	101	55.2	47.7	62.5	143	74.5	67.7	80.5
Loss of appetite													
	Any	50	27.8	21.4	34.9	44	24.0	18.0	30.9	53	27.6	21.4	34.5
	Grade 2 or 3	6	3.3	1.2	7.1	8	4.4	1.9	8.4	10	5.2	2.5	9.4
	Grade 3	0	0.0	0.0	2.0	0	0.0	0.0	2.0	0	0.0	0.0	1.9
	Causally related	46	25.6	19.4	32.6	43	23.5	17.6	30.3	52	27.1	20.9	34.0
Dose 3		N=177				N=180				N=191			
Drowsiness													
	Any	84	47.5	39.9	55.1	61	33.9	27.0	41.3	90	47.1	39.9	54.5
	Grade 2 or 3	19	10.7	6.6	16.3	12	6.7	3.5	11.4	23	12.0	7.8	17.5
	Grade 3	1	0.6	0.0	3.1	1	0.6	0.0	3.1	1	0.5	0.0	2.9
	Causally related	77	43.5	36.1	51.1	55	30.6	23.9	37.8	85	44.5	37.3	51.9
Irritability													
	Any	104	58.8	51.1	66.1	99	55.0	47.4	62.4	131	68.6	61.5	75.1
	Grade 2 or 3	34	19.2	13.7	25.8	29	16.1	11.1	22.3	48	25.1	19.1	31.9
	Grade 3	4	2.3	0.6	5.7	7	3.9	1.6	7.8	10	5.2	2.5	9.4
	Causally related	101	57.1	49.4	64.5	96	53.3	45.8	60.8	127	66.5	59.3	73.1
Loss of appetite													
	Any	53	29.9	23.3	37.3	40	22.2	16.4	29.0	65	34.0	27.3	41.2
	Grade 2 or 3	12	6.8	3.6	11.5	8	4.4	1.9	8.6	13	6.8	3.7	11.4
	Grade 3	1	0.6	0.0	3.1	1	0.6	0.0	3.1	3	1.6	0.3	4.5
	Causally related	49	27.7	21.2	34.9	34	18.9	13.5	25.4	61	31.9	25.4	39.1
Across doses		N=188				N=187*				N=198*			
Drowsiness													
	Any	145	77.1	70.5	82.9	131	70.1	62.9	76.5	159	80.3	74.1	85.6
	Grade 2 or 3	59	31.4	24.8	38.5	46	24.6	18.6	31.4	63	31.8	25.4	38.8
	Grade 3	8	4.3	1.9	8.2	6	3.2	1.2	6.9	9	4.5	2.1	8.5

	Causally related	139	73.9	67.0	80.1	128	68.4	61.3	75.0	154	77.8	71.3	83.4
Irritability													
	Any	157	83.5	77.4	88.5	158	84.5	78.5	89.4	185	93.4	89.0	96.5
	Grade 2 or 3	86	45.7	38.5	53.2	72	38.5	31.5	45.9	109	55.1	47.8	62.1
	Grade 3	14	7.4	4.1	12.2	14	7.5	4.2	12.2	25	12.6	8.3	18.1
	Causally related	155	82.4	76.2	87.6	155	82.9	76.7	88.0	181	91.4	86.6	94.9
Loss of appetite													
	Any	101	53.7	46.3	61.0	87	46.5	39.2	53.9	116	58.6	51.4	65.5
	Grade 2 or 3	22	11.7	7.5	17.2	26	13.9	9.3	19.7	28	14.1	9.6	19.8
	Grade 3	2	1.1	0.1	3.8	2	1.1	0.1	3.8	3	1.5	0.3	4.4
	Causally related	96	51.1	43.7	58.4	86	46.0	38.7	53.4	112	56.6	49.4	63.6
N = number of subjects with a symptom sheet completed n/% = number/percentage of subjects reporting the specified symptom 95% CI = 95% confidence interval (exact method for proportion); LL = lower limit, UL = upper limit Drowsiness Grade 2 = Drowsiness that interfered with normal activity Drowsiness Grade 3 = Drowsiness that prevented normal activity Irritability Grade 2 = Crying more than usual/interfered with normal activity Irritability Grade 3 = Crying that could not be comforted/prevented normal activity Loss of appetite Grade 2 = Eating less than usual/interfered with normal activity Loss of appetite Grade 3 = Not eating at all *post vaccination information not available for one subject in each group													

Secondary Outcome Variable (s):													
Incidence of solicited local symptoms (any intensity, grade 2 or grade 3 and grade 3) occurring within four days following DTaP/DTaP-HBV-IPV vaccination (Day 0 – Day 3), by dose and across doses– Total vaccinated cohort													
Symptom	Intensity	Separate Vaccine Group				Staggered Vaccine Group				Combination Vaccine Group			
		n	%	95% CI		n	%	95% CI		n	%	95% CI	
				LL	UL			LL	UL			LL	UL
Dose 1		N=186				N=187				N=198			
Pain	Any	86	46.2	38.9	53.7	72	38.5	31.5	45.9	89	44.9	37.9	52.2
	Grade 2 or 3	29	15.6	10.7	21.6	24	12.8	8.4	18.5	38	19.2	14.0	25.4
	Grade 3	6	3.2	1.2	6.9	8	4.3	1.9	8.3	8	4.0	1.8	7.8
Redness	Any	76	40.9	33.7	48.3	56	29.9	23.5	37.1	72	36.4	29.7	43.5
	Grade 2 or 3	21	11.3	7.1	16.7	17	9.1	5.4	14.2	20	10.1	6.3	15.2
	Grade 3	3	1.6	0.3	4.6	3	1.6	0.3	4.6	3	1.5	0.3	4.4
Swelling	Any	45	24.2	18.2	31.0	33	17.6	12.5	23.9	43	21.7	16.2	28.1
	Grade 2 or 3	17	9.1	5.4	14.2	14	7.5	4.2	12.2	21	10.6	6.7	15.8
	Grade 3	2	1.1	0.1	3.8	4	2.1	0.6	5.4	8	4.0	1.8	7.8
Dose 2		N=180				N=183				N=192			
Pain	Any	72	40.0	32.8	47.6	61	33.3	26.6	40.7	84	43.8	36.6	51.1
	Grade 2 or 3	29	16.1	11.1	22.3	16	8.7	5.1	13.8	34	17.7	12.6	23.9
	Grade 3	2	1.1	0.1	4.0	4	2.2	0.6	5.5	8	4.2	1.8	8.0
Redness	Any	83	46.1	38.7	53.7	68	37.2	30.1	44.6	97	50.5	43.2	57.8
	Grade 2 or 3	28	15.6	10.6	21.7	26	14.2	9.5	20.1	43	22.4	16.7	29.0

	Grade 3	6	3.3	1.2	7.1	12	6.6	3.4	11.2	10	5.2	2.5	9.4
Swelling	Any	48	26.7	20.4	33.8	45	24.6	18.5	31.5	69	35.9	29.2	43.2
	Grade 2 or 3	10	5.6	2.7	10.0	17	9.3	5.5	14.5	28	14.6	9.9	20.4
	Grade 3	3	1.7	0.3	4.8	5	2.7	0.9	6.3	6	3.1	1.2	6.7
Dose 3		N=177				N=180				N=191			
Pain	Any	71	40.1	32.8	47.7	54	30.0	23.4	37.3	77	40.3	33.3	47.6
	Grade 2 or 3	25	14.1	9.4	20.1	8	4.4	1.9	8.6	33	17.3	12.2	23.4
	Grade 3	1	0.6	0.0	3.1	2	1.1	0.1	4.0	6	3.1	1.2	6.7
Redness	Any	89	50.3	42.7	57.9	77	42.8	35.4	50.4	96	50.3	43.0	57.6
	Grade 2 or 3	37	20.9	15.2	27.6	27	15.0	10.1	21.1	31	16.2	11.3	22.2
	Grade 3	9	5.1	2.4	9.4	10	5.6	2.7	10.0	6	3.1	1.2	6.7
Swelling	Any	55	31.1	24.3	38.5	45	25.0	18.9	32.0	70	36.6	29.8	43.9
	Grade 2 or 3	13	7.3	4.0	12.2	13	7.2	3.9	12.0	22	11.5	7.4	16.9
	Grade 3	1	0.6	0.0	3.1	2	1.1	0.1	4.0	5	2.6	0.9	6.0
Across doses		N=188				N=187*				N=198*			
Pain	Any	118	62.8	55.4	69.7	98	52.4	45.0	59.7	126	63.6	56.5	70.3
	Grade 2 or 3	58	30.9	24.3	38.0	35	18.7	13.4	25.1	73	36.9	30.1	44.0
	Grade 3	8	4.3	1.9	8.2	10	5.3	2.6	9.6	18	9.1	5.5	14.0
Redness	Any	125	66.5	59.3	73.2	102	54.5	47.1	61.8	135	68.2	61.2	74.6
	Grade 2 or 3	62	33.0	26.3	40.2	48	25.7	19.6	32.6	67	33.8	27.3	40.9
	Grade 3	14	7.4	4.1	12.2	20	10.7	6.7	16.0	16	8.1	4.7	12.8
Swelling	Any	84	44.7	37.4	52.1	70	37.4	30.5	44.8	102	51.5	44.3	58.7
	Grade 2 or 3	29	15.4	10.6	21.4	30	16.0	11.1	22.1	45	22.7	17.1	29.2
	Grade 3	5	2.7	0.9	6.1	9	4.8	2.2	8.9	16	8.1	4.7	12.8

N = number of subjects with a symptom sheet completed

n/% = number/percentage of subjects reporting the specified symptom

95% CI = 95% confidence interval (exact method for proportion); LL = lower limit, UL = upper limit

Pain Grade 2 = Cried/protected on touch

Pain Grade 3 = Cried when limb was moved/spontaneously painful

Redness or Swelling Grade 2 = > 5 mm to ≤ 20 mm

Redness or Swelling Grade 3 = > 20 mm

*post vaccination information not available for one subject in each group

Secondary Outcome Variable (s): Concomitant medication reported within four days following DTap/DTaP-HBV-IPV vaccination (Day 0 – Day 3) – Total vaccinated cohort

		Separate Vaccine Group				Staggered Vaccine Group				Combination Vaccine Group			
				95% CI				95% CI				95% CI	
				LL	UL			LL	UL			LL	UL
Dose 1		N = 187				N = 187				N = 198			
	Any medication	91	48.7	41.3	56.1	78	41.7	34.6	49.1	91	46.0	38.9	53.2
	Any Antibiotic	2	1.1	0.1	3.8	2	1.1	0.1	3.8	1	0.5	0.0	2.8
	Any Antipyretic	79	42.2	35.1	49.7	70	37.4	30.5	44.8	84	42.4	35.4	49.6
	Antipyretic Prophylactic	24	12.8	8.4	18.5	12	6.4	3.4	10.9	15	7.6	4.3	12.2
	Antipyretic for fever	20	10.7	6.7	16.0	25	13.4	8.8	19.1	39	19.7	14.4	25.9

Dose 2		N = 180				N = 183				N = 192			
	Any medication	83	46.1	38.7	53.7	60	32.8	26.0	40.1	101	52.6	45.3	59.8
	Any Antibiotic	1	0.6	0.0	3.1	1	0.5	0.0	3.0	2	1.0	0.1	3.7
	Any Antipyretic	78	43.3	36.0	50.9	51	27.9	21.5	35.0	91	47.4	40.2	54.7
	Antipyretic Prophylactic	10	5.6	2.7	10.0	5	2.7	0.9	6.3	8	4.2	1.8	8.0
	Antipyretic for fever*	25	13.9	9.2	19.8	18	9.8	5.9	15.1	47	24.5	18.6	31.2
Dose 3		N = 177				N = 180				N = 191			
	Any medication	73	41.2	33.9	48.9	57	31.7	24.9	39.0	89	46.6	39.4	53.9
	Any Antibiotic	4	2.3	0.6	5.7	9	5.0	2.3	9.3	6	3.1	1.2	6.7
	Any Antipyretic	66	37.3	30.1	44.9	43	23.9	17.9	30.8	75	39.3	32.3	46.6
	Antipyretic Prophylactic	5	2.8	0.9	6.5	2	1.1	0.1	4.0	5	2.6	0.9	6.0
	Antipyretic for fever	26	14.7	9.8	20.8	11	6.1	3.1	10.7	37	19.4	14.0	25.7
Across doses		N = 188				N = 187*				N = 198*			
	Any medication	136	72.3	65.4	78.6	123	65.8	58.5	72.5	156	78.8	72.4	84.3
	Any Antibiotic	6	3.2	1.2	6.8	11	5.9	3.0	10.3	9	4.5	2.1	8.5
	Any Antipyretic	129	68.6	61.5	75.2	104	55.6	48.2	62.9	145	73.2	66.5	79.3
	Antipyretic Prophylactic	34	18.1	12.9	24.3	17	9.1	5.4	14.2	25	12.6	8.3	18.1
	Antipyretic for fever	53	28.2	21.9	35.2	46	24.6	18.6	31.4	89	44.9	37.9	52.2

N = number of subjects with at least one medication screen completed
n/% = number/percentage of subjects for whom the specified concomitant medication was given
95% CI = 95% confidence interval (exact method for proportion); LL = lower limit, UL = upper limit
*post vaccination information not available for one subject in each group

Secondary Outcome Variable (s): Number (%) of subjects with unsolicited adverse events during the extended follow-up period beyond 31 days following last vaccine dose (ESFU cohort)			
Most frequent 10 unsolicited Adverse Events	Separate Vaccine Group N=182	Staggered Vaccine Group N= 184	Combination Vaccine Group N=194
Subjects with any AE(s), n(%)	154 (84.6)	164 (89.1)	165 (85.1)
upper respiratory tract infection	78 (42.9)	85 (46.2)	84 (43.3)
otitis media	46 (25.3)	48 (26.1)	56 (28.9)
rhinitis	38 (20.9)	30 (16.3)	30 (15.5)
injection site reaction	24 (13.2)	33 (17.9)	27 (13.9)
infection viral	14 (7.7)	24 (13.0)	24 (12.4)
tooth ache	25 (13.7)	21 (11.4)	14 (7.2)
diarrhea	23 (12.6)	15 (8.2)	13 (6.7)
vomiting	14 (7.7)	21 (11.4)	10 (5.2)
conjunctivitis	10 (5.5)	20 (10.9)	11 (5.7)
coughing	12 (6.6)	13 (7.1)	15 (7.7)
moniliasis	9 (4.9)	14 (7.6)	12 (6.2)
constipation	9 (4.9)	12 (6.5)	12 (6.2)
fever	10 (5.5)	14 (7.6)	9 (4.6)
dermatitis contact	4 (2.2)	17 (9.2)	10 (5.2)
rash	10 (5.5)	10 (5.4)	10 (5.2)
pneumonia	7 (3.8)	5 (2.7)	14 (7.2)

Safety Results: Number (%) of subjects with unsolicited Adverse Events occurring within the active phase from dose 1 to day 30 following last vaccine dose (Total vaccinated cohort)

Most frequent unsolicited Adverse Events	Separate Vaccine Group N=188	Staggered Vaccine Group N= 187*	Combination Vaccine Group N=198*
Subjects with any AE(s), n(%)	154 (81.9)	164 (87.7)	165 (83.3)
upper respiratory tract infection	78 (41.5)	85 (45.5)	84 (42.4)
otitis media	46 (24.5)	48 (25.7)	56 (28.3)
rhinitis	38 (20.2)	30 (16.0)	30 (15.2)
injection site reaction	24 (12.8)	33 (17.6)	27 (13.6)
infection viral	14 (7.4)	24 (12.8)	24 (12.1)
tooth ache	25 (13.3)	21 (11.2)	14 (7.1)
diarrhea	23 (12.2)	15 (8.0)	13 (6.6)
vomiting	14 (7.4)	21 (11.2)	10 (5.1)
conjunctivitis	10 (5.3)	20 (10.7)	11 (5.6)
coughing	12 (6.4)	13 (7.0)	15 (7.6)
moniliasis	9 (4.8)	14 (7.5)	12 (6.1)
constipation	9 (4.8)	12 (6.4)	12 (6.1)
fever	10 (5.3)	14 (7.5)	9 (4.5)
dermatitis contact	4 (2.1)	17 (9.1)	10 (5.1)
rash	10 (5.3)	10 (5.3)	10 (5.1)
pneumonia	7 (3.7)	5 (2.7)	14 (7.1)
*post vaccination information not available for one subject in each group			

Safety Results: Number (%) of Serious Adverse Events (SAEs) [number of SAE considered by the investigator to be related to study medication] (Total vaccinated cohort)			
Serious Adverse Events throughout the entire study period including extended safety follow-up period after last vaccine dose	Separate Vaccine Group N=188	Staggered Vaccine Group N= 187*	Combination Vaccine Group N=198*
Subjects with any SAE(s), n(%) [n related]	9 (4.8) [0]	6 (3.2) [1]	9 (4.5) [0]
asthma	1 (0.5) [0]	0 (0.0) [0]	1 (0.5) [0]
bronchospasm	2 (1.1) [0]	0 (0.0) [0]	0 (0.0) [0]
cellulitis	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
convulsions	0 (0.0) [0]	1 (0.5) [0]	1 (0.5) [0]
dehydration	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]
fever	2 (1.1) [0]	1 (0.5) [0]	0 (0.0) [0]
gastroenteritis	2 (1.1) [0]	1 (0.5) [0]	2 (1.0) [0]
gastroesophageal reflux	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
infection viral	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
neoplasm nos	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
neuropathy	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
otitis media	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
pneumonia	3 (1.6) [0]	1 (0.5) [0]	4 (2.0) [0]
pneumonitis	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
pyelonephritis	0 (0.0) [0]	1 (0.5) [1]	0 (0.0) [0]
urinary tract infection	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Fatal Serious Adverse Events throughout the entire study period including extended safety follow-up period after last vaccine dose	Separate Vaccine Group N=188	Staggered Vaccine Group N= 187*	Combination Vaccine Group N=198*
Subjects with fatal SAE(s), n (%) [n related]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
*post vaccination information not available for one subject in each group			

5 **Conclusion:** One month after the third dose of the DTaP-HepB-IPV vaccine given concomitantly with
Hib and PnC, geometric mean antibody concentrations for each of the pertussis antigens, and
seroprotection rates for diphtheria, tetanus and the polioviruses, were shown to be non-inferior to those
10 achieved following separately administered vaccines. Unsolicited adverse events were reported in 154
(81.9%) of the separate vaccine group, 164 (87.7%) of the staggered vaccine group and 165 (83.3%) of
the combined vaccine group, with the most frequently reported in each group being upper respiratory
tract infection and otitis media. Non-fatal serious adverse events were reported in 9 (4.8%) of the
separate vaccine group, 6 (3.2%) of the staggered vaccine group and 9 (4.5) of the combined vaccine
15 group. Pneumonia, bronchospasm, fever and gastroenteritis were the only non-fatal serious adverse
events reported in more than one subject in the separate vaccine group. No single non-fatal serious
adverse event was reported in more than one subject in the staggered vaccine group and pneumonia
and gastroenteritis were the only events reported by more than one subject in the combined vaccine
group. No deaths were reported.

15

REFERENCES (the contents of which are hereby incorporated by reference)

- [1] Armand et al. (1982) *J. Biol. Stand.* 10:335-339.
- [2] Cadoz et al. (1985) *Vaccine* 3:340-342.
- [3] *MMWR* (1997) 46(RR-5) 1-10.
- 5 [4] Baklaic et al. (1983) *Infect. Immun.* 42:599-604.
- [5] Jones (2001) *Curr Opin Investig Drugs* 2:47-49.
- [6] Costantino et al. (1992) *Vaccine* 10:691-8.
- [7] Lieberman et al. (1996) *JAMA* 275:1499-503.
- [8] W02005/000345.
- 10 [9] W002/058737.
- [10] W003/007985.
- [11] Rennels et al. (2002) *Pediatr Infect Dis J* 21:978-979.
- [12] W02004/013400.
- [13] Campbell et al. (2002) *J Infect Dis* 186:1848-1851.
- 15 [14] Herzenberg et al. (1980) *Nature* 285: 664-667.
- [15] Schutze et al. (1985) *J Immunol* 135:2319-2322.
- [16] Dagan et al. (1998) *Infect Immun* 66:2093-2098.
- [17] Barington et al. (1994) *Infect Immun* 62:9-14.
- [18] Di John et al. (1989) *Lancet* 2(8677):1415-8.
- 20 [19] Granoff et al. (1993) *Vaccine Suppl*: S46-51.
- [20] Granoff et al. (1994) *JAMA* 272:1116-1121.
- [21] Barington et al. (1993) *Infect Immun* 61:432-438.
- [22] Australian patent 748716 (granted from W098/51339).
- [23] Olander et al. (2001) *Vaccine* 20:336-341.
- 25 [24] Burrage et al. (2002) *Infect Immun* 70:4946-4954.
- [25] Peeters et al. (1999) *Infect Immun* 59:3504-3510.

- [26] Hoppenbrouwers et al. (1999) *Vaccine* 17:2588-98.
- [27] W002/00249.
- [28] WO00/56360.
- [29] Reddin et al. (2001) *FEMS Immunol Med Microbiol* 31:153-162.
- 5 [30] Podda et al. (1991) *Vaccine* 9:741-745.
- [31] Darkes & Plosker (2002) *Paediatr Drugs* 4:609-630.
- [32] *Vaccines*. (eds. Plotkin & Orenstein). 4th edition, 2004, ISBN: 0- 7216-9688-0.
- [33] Del Giudice et al. (1998) *Molecular Aspects of Medicine* 19:1-70.
- [34] Anonymous (Jan 2002) *Research Disclosure*, 453077.
- 10 [35] Anderson (1983) *Infect Immun* 39(1):233-238.
- [36] Anderson et al. (1985) *J Clin Invest* 76(1):52-59.
- [37] Ramsay et al. (2001) *Lancet* 357(9251):195-196.
- [38] Lindberg (1999) *Vaccine* 17 Suppl 2:S28-36.
- [39] Buttery & Moxon (2000) *JR Coll Physicians Lond* 34:163-168.
- 15 [40] Ahmad & Chapnick (1999) *Infect Dis Clin North Am* 13:113-33, vii.
- [41] Goldblatt (1998) *J. Med. Microbiol.* 47:563-567.
- [42] European patent 0477508.
- [43] US patent 5,306,492.
- [44] WO98/42721.
- 20 [45] Dick et al. in *Conjugate Vaccines* (eds. Cruse et al.) Karger, Basel, 1989, 10:48-114.
- [46] Hermanson *Bioconjugate Techniques*, Academic Press, San Diego (1996) ISBN: 0123423368.
- [47] W003/080678.
- 25 [48] Glode et al. (1979) *J Infect Dis* 139:52-56
- [49] W094/05325; US patent 5,425,946.
- [50] United Kingdom patent application 0323103.2.

- [51] WO99/42130
- [52] W096/40242
- [53] Lees et al. (1996) *Vaccine* 14:190- 198.
- [54] W095/08348.
- 5 [55] US patent 4,882,317
- [56] US patent 4,695,624
- [57] Porro et al. (1985) *Mol Immunol* 22:907-919.
- [58] EP-A-0208375
- [59] WO00/10599
- 10 [60] Gever et al. *Med. Microbiol. Immunol*, 165: 171-288 (1979).
- [61] US patent 4,057,685.
- [62] US patents 4,673,574; 4,761,283; 4,808,700.
- [63] US patent 4,459,286.
- [64] US patent 4,965,338
- 15 [65] US patent 4,663,160.
- [66] US patent 4,761,283
- [67] US patent 4,356,170
- [68] Balmer & Borrow (2004) *Expert Rev Vaccines* 3:77-87.
- [69] Watson (2000) *Pediatr infect Dis J* 19:331 -332.
- 20 [70] Rubin (2000) *Pediatr Clin North Am* 47:269-285, v.
- [71] Jedrzejewski (2001) *Microbiol Mol Biol Rev* 65:187-207.
- [72] Zielen et al. (2000) *infect. Immun.* 68:1435-1440.
- [73] Kanra et al. (1999) *The Turkish Journal of Paediatrics* 42:421-427.
- [74] Ravenscroft et al. (2000) *Dev Biol (Basel)* 103: 35-47.
- 25 [75] W097/00697.
- [76] W096/37222; US patent 6,333,036.

- [77] W02004/032958
- [78] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th ed. ISBN: 0683306472.
- [79] Almeida & Alpar (1996) J. Drug Targeting 3:455-467.
- 5 [80] Agarwal & Mishra (1999) Indian JExp Biol 37:6-16.
- [81] Vaccine Design(1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
- [82] WO00/23105.
- [83] WO90/14837.
- [84] US patent 5,057,540.
- 10 [85] W096/33739.
- [86] EP-A-0109942.
- [87] WO96/11711.
- [88] WO00/07621.
- [89] Barr et al. (1998) Idvanced Drug Delivey Reviews 32:247-271.
- 15 [90] Sjolanderet et al. (1998) Advanced Drug Delivery Reviews 32:321-338.
- [91] Nilkura et al. (2002) Virology 293:273-280.
- [92] Lenz et al. (2001) JImmunol 166:5346-5355.
- [93] Pinto et al. (2003) JInfect Dis 188:327-338.
- [94] Gerber et al. (2001) Virol 75:4752-4760.
- 20 [95] W003/024480
- [96] WO03/024481
- [97] Glucketal. (2002) Vaccine20:B10- B16.
- [98] EP-A-0689454.
- [99] Johnson et al. (1999) BioorgMed Chem Lett 9:2273-2278.
- 25 [100] Evans et al. (2003) Expert Rev vaccines 2:219-229.
- [101] Meraldi et al. (2003) Vaccine 21:2485-2491.
- [102] Pajak et al. (2003) Vaccine 21:836-842.

- [103] Kandimalla et al. (2003) *Nucleic Acids Research* 31:2393-2400.
- [104] W002/26757.
- [105] WO99/62923.
- [106] Krieg (2003) *Nature Medicine* 9:831-835.
- 5 [107] McCluskie et al. (2002) *FEMS Immunology and Medical Microbiology* 32:179-185.
- [108] WO98/40100.
- [109] US patent 6,207,646.
- [110] US patent 6,239,116.
- 10 [111] US patent 6,429,199.
- [112] Kandimalla et al. (2003) *Biochemical Society Transactions* 31 (part 3):654-658.
- [113] Blackwell et al. (2003) *J Immunol* 170:4061-4068.
- [114] Krieg (2002) *Trends Immunol* 23:64-65.
- [115] WO01/95935.
- 15 [116] Kandimalla et al. (2003) *BBRC* 306:948-953.
- [117] Bhagat et al. (2003) *BBRC* 300:853-861.
- [118] W003/035836.
- [119] WO95/17211.
- [120] W098/42375.
- 20 [121] Beignon et al. (2002) *Infect Immun* 70:3012-3019.
- [122] Pizza et al. (2001) *Vaccine* 19:2534-2541.
- [123] Pizza et al. (2000) *Int J Med Microbiol* 290:455-461.
- [124] Scharon-Kersten et al. (2000) *Infect Immun* 68:5306-5313.
- [125] Ryan et al. (1999) *Infect Immun* 67:6270-6280.
- 25 [126] Partidos et al. (1999) *Immunol Lett* 67:209-216.
- [127] Peppoloni et al. (2003) *Expert Rev Vaccines* 2:285-293.
- [128] Pine et al. (2002) *J Control Release* 85:263-270.

- [129] Domenighini et al. (1995) *Mol Microbiol* 15:1165-1167.
- [130] WO99/40936.
- [131] WO99/44636.
- [132] Singh et al (2001) *J Cont Release* 70:267-276.
- 5 [133] WO99/27960.
- [134] US patent 6,090,406
- [135] US patent 5,916,588
- [136] EP-A- 0626169.
- [137] WO99/52549.
- 10 [138] WO01/21207
- [139] WO01/21152.
- [140] Andrianov et al. (1998) *Biomaterials* 19:109-115.
- [141] Payne et al. (1998) *AdvDrugDeliveryReview* 31:185-196.
- [142] Stanley (2002) *Clin Exp Dermatol* 27:571-577.
- 15 [143] Jones (2003) *Curr Opin Investig Drugs* 4:214-218.
- [144] W004/60308
- [145] W004/64759.
- [146] WO99/11241.
- [147] W094/00153.
- 20 [148] W098/57659.
- [149] European patent applications 0835318, 0735898 and 0761231.
- [150] WO03/009869.
- [151] WO2004/110480.
- [152] Olander et al. (2002) *Vaccine* 20:336-41.
- 25 [153] McVernon et al. (2003) *Vaccine* 21:2573-9.
- [154] Chippaux et al. (2004) *Vaccine* 22:3303-11.

CLAIMS

1. A method for immunising a human patient against a disease caused by *Neisseria meningitidis*, comprising the step of administering to the human patient a composition that comprises at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof.
2. A method for immunising a human patient against a disease caused by *Neisseria meningitidis*, comprising the step of administering to the human patient a composition that comprises at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid, wherein the patient has been pre-immunised with (a) a tetanus toxoid and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N. meningitidis* and (ii) a tetanus toxoid.
3. The use of at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (b) a conjugate of (i) the capsular saccharide of serogroup C *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N. meningitidis* and (ii) a tetanus toxoid or derivative thereof; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by *Neisseria meningitidis*, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid or derivative thereof.
4. The use of at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A *N.meningitidis* and (ii) a tetanus toxoid; (b) a conjugate of (i) the capsular saccharide of serogroup C *N. meningitidis* and (ii) a tetanus toxoid; (c) a conjugate of (i) the capsular saccharide of serogroup W135 *N.meningitidis* and (ii) a tetanus toxoid; and (d) a conjugate of (i) the capsular saccharide of serogroup Y *N.meningitidis* and (ii) a tetanus toxoid, in the manufacture of a medicament for immunising a human patient against a disease caused by *Neisseria meningitidis*, wherein the patient has been pre-immunised with (a) a tetanus toxoid and/or (b) a conjugate of (i) a capsular saccharide of an organism other than *N.meningitidis* and (ii) a tetanus toxoid.
5. The method of claim 1 or 2, wherein the composition comprises (a) and (b), (b) and (d), or all four of (a), (b), (c) and (d).
6. The use of claim 3 or 4, wherein the use is of (a) and (b), (b) and (d), or all four of (a), (b), (c) and (d).

7. The method or use of any preceding claim, wherein the patient has been pre-immunised with a vaccine comprising a tetanus toxoid.
8. The method or use of any preceding claim, wherein the patient has been pre-immunised with a vaccine comprising a Hib conjugate.
- 5 9. The method or use of any preceding claim, wherein the patient has been pre-immunised with a vaccine comprising at least one pneumococcal conjugate.
10. The method or use of any preceding claim, wherein the patient was pre-immunised at least 0.5, 1, 2, 4 or 6 months before the method or use.
- 10 11. The method or use of claim 10, wherein the patient was pre-immunised at least 8 years before the method or use.
12. The method or use of any preceding claim, wherein the pre-immunisation took place within 1 year of the patient's birth.
13. The method or use of any preceding claim, wherein the saccharides in the meningococcal conjugates (a) to (d) are shorter than the native capsular saccharides
15 seen in meningococcus.
14. The method or use of any preceding claim, wherein the meningococcal conjugates comprise a tetanus toxoid carrier and an adipic acid linker.
15. The method or use of claim 14, comprising no more than 50µg of tetanus toxoid carrier.
- 20 16. The method or use of any preceding claim, wherein the composition or medicament further comprises a conjugated capsular saccharide from *Streptococcus pneumoniae*.
17. The method or use of any preceding claim, wherein the composition or medicament further comprises a conjugated capsular saccharide from *Haemophilus*
25 *influenzae* type B.
18. The method or use of any preceding claim, wherein the composition or medicament further comprises a protein antigen from serogroup B of *Neisseria meningitidis*.
19. The method or use of any preceding claim, wherein the composition or
30 medicament includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.
20. The method or use of any preceding claim, wherein the disease caused by *Neisseria meningitidis* is meningococcal meningitis.
21. The method or use of claims 1-6, wherein: - the patient has been pre-immunised,
35 at least five years before the method or use, with a vaccine comprising a tetanus toxoid; - the meningococcal conjugates comprise a tetanus toxoid carrier and, optionally, an adipic acid linker; - the meningococcal conjugates are present at 2-15 µg/ml (measured as meningococcal saccharide) per serogroup; - the

saccharide:carrier weight ratio for at least one conjugate is about 1:3; and - the medicament includes 20-50 µg/ml of tetanus toxoid.

22. A method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to a diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with (a) a diphtheria toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

23. A method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to tetanus toxoid or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof.

24. A method for immunising a human patient against a disease caused by *Streptococcus pneumoniae*, comprising the step of administering to the human patient a composition that comprises at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof and at least one of which is conjugated to diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof and (c) a diphtheria toxoid or derivative thereof and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

25. The use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to a diphtheria toxoid or CRM197 or a derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a diphtheria toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.

26. The use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which conjugated to a tetanus toxoid or a derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof.

27. The use of at least seven, ten, eleven, thirteen or fourteen conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof and at least one of which is conjugated to

- diphtheria toxoid or CRM197 or a derivative thereof, in the manufacture of a medicament for immunising a human patient against a disease caused by pneumococcus, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof and (c) a diphtheria toxoid or derivative thereof and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.
28. The method or use of claims 22-27, wherein a meningococcal capsular saccharide conjugate is not present in the composition or medicament.
29. The method or use of claims 22-28, wherein the patient has been pre-immunised with a vaccine comprising a diphtheria toxoid.
30. The method or use of claims 22-29, wherein the patient has been pre-immunised with a vaccine comprising a tetanus toxoid.
31. The method or use of claims 22-30, wherein the patient has been pre-immunised with a vaccine comprising a Hib conjugate.
32. The method or use of claims 22-31, wherein the patient has been pre-immunised with a vaccine comprising at least one meningococcal capsular saccharide conjugate.
33. The method or use of claims 22-32, wherein the patient was pre-immunised at least 0.5, 1, 2, 4 or 6 months before the method or use.
34. The method or use of claim 33, wherein the patient was pre-immunised at least 8 years before the method or use.
35. The method or use of claims 22-34, wherein the pre- immunisation took place within 1 year of the patient's birth.
36. The method or use of claims 22-35, wherein at least one of the saccharides in the pneumococcal conjugates are shorter than the native capsular saccharides seen in pneumococcus.
37. The method or use of claims 22-36, wherein at least one of the pneumococcal conjugates comprises a diphtheria toxoid carrier and, optionally, an adipic acid linker.
38. The method or use of claims 22-37, wherein at least one of the pneumococcal conjugates comprises a CRM197 carrier and, optionally, an adipic acid linker.
39. The method or use of claims 22-38, wherein at least one of the pneumococcal conjugates comprises a tetanus toxoid carrier and, optionally, an adipic acid linker.
40. The method or use of claim 37 or 38, comprising no more than 60µg of diphtheria toxoid or CRM197 carrier.
41. The method or use of claim 39, comprising no more than 50µg of tetanus toxoid carrier.

42. The method or use of claims 22-41, wherein the composition or medicament further comprises a conjugated capsular saccharide from *Haemophilus influenzae* type B.

5 43. The method or use of claims 22-42, wherein the composition or medicament further comprises a protein antigen from serogroup B of *Neisseria meningitidis*.

44. The method or use of claims 22-43, wherein the composition or medicament includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.

10 45. A method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

	Visit 1	Visit 2	Visit 3	Visit 4
DTP	X		X	
Strep		X		X
MenC		X		X

15 wherein the visit to the medical practitioner all occur in the first 8 months of life,
 wherein there is at least 2 weeks between each consecutive visit,
 wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
 20 wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,
 wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

25

46. A method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

30

	Visit 1	Visit 2	Visit 3	Visit 4
DTP	X	X	X	
Strep	X		X	
MenC		X		Optionally X

35 wherein the visit to the medical practitioner all occur in the first 8 months of life,
 wherein there is at least 2 weeks between each consecutive visit,
 wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
 wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,

wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

- 5 47. A method for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae* comprising the step of administering to the human patient the following vaccines with the following administration scheme:

	Visit 1	Visit 2	Visit 3
DTP	X	X	X
Strep	X	X	
MenC		X	X

- 10 wherein the visit to the medical practitioner all occur in the first 8 months of life, wherein there is at least 2 weeks between each consecutive visit, wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
- 15 wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes, wherein MenC comprises a conjugated *N. meningitidis* serogroup C capsular saccharide,
- 20 wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.

- 25 48. The method of claims 45-47, wherein Visits 1, 2 and 3 occur at: 2, 3, 4 months of age; 3, 4, 5 months of age; 2, 4, 6 months of age; or 6, 10, 14 weeks of age.

49. The method of claims 45-48, wherein visit 4 occurs at 5 months of age.

50. The method of claims 45-49, wherein DTP, MenC and Strep are administered as separate injections at any one visit.

- 30 51. The method of claims 45-49, wherein DTP, MenC and Strep are administered as a combination vaccine at any one visit.

- 35 52. The method of claims 45-51, wherein MenB, a *N. meningitidis* subunit protein vaccine or a *N. meningitidis* outer membrane vesicle vaccine (preferably isolated from a serogroup B strain), is administered at Visit 1 and Visit 3.

53. The method of claim 52, wherein MenB is given as a booster dose at a further visit at 11-15 months of age.

- 40 54. The method of claims 45-53, wherein DTP is given as a booster dose at a further visit at 11-15 months of age.

- 45 55. The method of claims 45-54, wherein MenC is given as a booster dose at a further visit at 11-15 months of age.

56. The method of claims 45-55, wherein Strep is given as a booster dose at a further visit at 11-15 months of age.

57. The method of claims 45-56, wherein DTP further comprises HepB surface antigen (optionally adsorbed onto aluminium phosphate).
- 5 58. The method of claims 45-57, wherein DTP further comprises inactivated polio virus.
59. The method of claims 45-58, wherein MenC further comprises a conjugated *N. meningitidis* serogroup A capsular saccharide which is optionally conjugated to the
10 same protein carrier as MenC.
60. The method of claims 45-59, wherein MenC further comprises a conjugated *N. meningitidis* serogroup Y capsular saccharide which is optionally conjugated to the
15 same protein carrier as MenC.
61. The method of claims 45-60, wherein MenC further comprises a conjugated *N. meningitidis* serogroup W135 capsular saccharide which is optionally conjugated to the same protein carrier as MenC.
- 20 62. The method of claims 45-61, wherein MenC further comprises a conjugated *H. influenzae* type B capsular saccharide which is optionally conjugated to the same protein carrier as MenC.
- 25 63. The method of claims 45-61, wherein DTP further comprises a conjugated *H. influenzae* type B capsular saccharide which is optionally conjugated to the same protein carrier as MenC.
64. The method of claims 45-63, wherein at least one capsular saccharide is conjugated to TT in the MenC and Strep vaccines.
30
65. The method of claims 45-64, wherein at least one capsular saccharide is conjugated to DT in the MenC and Strep vaccines.
- 35 66. The method of claims 45-65, wherein at least one capsular saccharide is conjugated to CRM197 in the MenC and Strep vaccines.
67. The use of the vaccines of claims 45-66 in the manufacture of a medicament for immunising a human patient against a disease caused by *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheriae* and *Streptococcus pneumoniae*, wherein the patient is administered vaccine according to
40 the vaccination schedule of claims 45-67.
68. A kit comprising all the vaccines required for Visit 1 vaccine administration of claims 45-67, and instructions for its use.
- 45 69. A kit comprising all the vaccines required for Visit 2 vaccine administration of claims 45-67, and instructions for its use.
70. A kit comprising all the vaccines required for Visit 3 vaccine administration of claims 45-67, and instructions for its use.